Document:

EX-10.1

 Exhibit 10.1 
 EXECUTIVE EMPLOYMENT AGREEMENT 
 This EXECUTIVE EMPLOYMENT AGREEMENT
(this “Agreement”) is entered into as of the Effective Date set out in paragraph 1, by and between Cornerstone Therapeutics Inc., a Delaware corporation (the “Company”), and Andreas Maetzel, M.D., M.Sc., Ph.D.,.
(the “Executive”). 
 WHEREAS, the Company desires to employ the Executive and enter into this Agreement, which
will set forth the terms and conditions under which the Executive will serve the Company and its affiliates; and 
 WHEREAS, the
Executive wishes to be employed by the Company on the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration
of the premises and mutual agreements hereinafter contained, the parties hereto agree as follows: 
 1. Term of
Employment. The Company hereby agrees to employ the Executive, and the Executive hereby accepts employment with the Company, upon the terms set forth in this Agreement, for the period commencing on the later of (a) April 18, 2013
or (b) the date three (3) business days after the date appearing on the Form I-797 Notice of Action as the date on which the Executive’s I-129 petition for O-1 immigration status was approved (the “Effective Date”) and
ending on the date that the Agreement is terminated in accordance with the provisions of Section 4. 
 2. Title;
Capacity. The Executive shall serve as Vice President, Clinical and Regulatory, and in such other positions as the Company or its Board of Directors (the “Board”) may determine from time to time. The Executive shall be based
at the Company’s office in Cary, North Carolina. The Executive shall be subject to the supervision of, and shall have such authority as is delegated to him by, the Chief Executive Officer of the Company or his designee. 

The Executive hereby accepts such employment and agrees to undertake the duties and responsibilities inherent in such position and such
other duties and responsibilities as the Chief Executive Officer or his designee shall from time to time reasonably assign to him. The Executive agrees to devote his entire business time, attention and energies to the business and interests of the
Company during the employment period; provided, however, that the Executive may serve as a consultant or a member of an advisory board or a board of directors with the prior consent of the Board. The Executive agrees to abide by any
rules, regulations, instructions, personnel practices and policies of the Company that are applicable to him and any changes therein that may be adopted from time to time by the Company. 

 3. Compensation and Benefits. 

3.1. Salary. The Company shall pay the Executive a base salary in accordance with its regular payroll practices at an annualized
rate of $250,000.00, less lawful deductions. Such salary shall be subject to adjustment thereafter as determined by the Board. 

3.2. Annual Target Cash Bonus. The Executive shall be eligible to receive an annual target cash bonus of up to thirty-five
(35%) percent of his then annual base salary (“Target Cash Bonus”). The Board (or a committee thereof) shall determine the amount of the actual award, if any, based on overall corporate performance and individual performance.
Actual awards may be greater than or less than the Executive’s Target Cash Bonus, depending in part upon the extent to which actual performance exceeds or falls below the performance goals. Any bonus shall be paid in a single lump sum, subject
to lawful deductions, at such time as bonuses are regularly paid to senior executives of the Company, but in any event such bonus shall be paid on or before March 15 of the year following the year to which the bonus relates. Except as may be
expressly provided below, the Executive must be employed on the date that the bonus is paid to be eligible for any Target Cash Bonus. Each cash bonus award that may become payable shall be paid solely from the general assets of the Company.
Notwithstanding the foregoing, so long as the Effective Date occurs before June 30, 2013, the Executive shall be eligible to receive a prorated Target Cash Bonus for 2013, prorated by dividing the number of days employed by 365. The Executive
shall also be eligible to receive an annual equity awards on similar terms and conditions as may be applicable to other senior executives of the Company, which in respect to 2013, shall be prorated according to the formula set forth above.

 3.3. Grant of Restricted Stock and Stock Options. The Executive will be granted, effective as of the Effective Date,
twenty-five (25,000) thousand shares of restricted common stock and options to acquire twenty-five (25,000) thousand shares of common stock. The grant shall be on such terms and conditions as are described in Appendix A hereto, and
the documents referenced therein. 
 3.4. Fringe Benefits. The Executive shall be entitled to participate in all bonus
and benefit programs (excluding the Company’s Cash Bonus Program for Employees (Other than Executive Officers)) that the Company establishes and makes available to its employees or executives, if any, to the extent that the Executive’s
position, tenure, salary, age, health and other qualifications make him eligible to participate; provided, however, the Executive’s participation is subject to the applicable terms, conditions and eligibility requirements of these
plans as they may exist from time to time. The Executive shall be entitled to accrue 1.67 vacation days per month (four (4) weeks per year), and, if requested in writing by the Chief Executive Officer, such vacation time shall be taken at such
times as may be approved by the Chief Executive Officer or his designee. Accrued but unused vacation at the end of each year will not carry over past January 31 of the next year, except to the extent provided for in Company policies.

 3.5. Reimbursement of Expenses. The Company shall reimburse the Executive for all reasonable travel, entertainment
and other expenses incurred or paid by the Executive in connection with, or related to, the performance of his duties, responsibilities or services under this Agreement, in accordance with the Company’s expense reimbursement policy, including
the Executive’s presentation of documentation, expense statements, vouchers and/or such other supporting information as the Company may request, provided, however, that the amount

  
 -2-

 
available for such travel, entertainment and other expenses may be fixed in advance by the Board. Notwithstanding the foregoing, (i) the expenses eligible for reimbursement in any particular
taxable year may not affect the expenses eligible for reimbursement in any other taxable year, (ii) such reimbursement must be made on or before the last day of the year following the year in which the expense was incurred, and (iii) the
right to reimbursement is not subject to liquidation or exchange for another benefit. 
 4. Employment
Termination. The employment of the Executive by the Company pursuant to this Agreement shall terminate upon the occurrence of any of the following: 
 4.1. At the election of the Company, for Cause, immediately upon written notice by the Company to the Executive; 
 4.2. At the election of the Executive, for Good Reason, upon written notice by the Executive to the Company; 
 4.3. At the election of the Company without Cause during a Change of Control Period (as defined in Section 20) or at the election of the Executive for Good Reason during a Change of Control Period;

 4.4. Upon the death or Disability (as defined in Section 20) of the Executive; 

4.5. At the election of the Executive, without Good Reason, by providing written notice to the Company at least ninety (90) days
prior to such termination; and 
 4.6. At the election of the Company, without Cause, by providing written notice to the
Executive at least ninety (90) days prior to such termination. 
 5. Effect of Termination. 

5.1. Termination for Cause. In the event the Executive’s employment is terminated for Cause pursuant to Section 4.1,
the Company shall pay to the Executive the compensation and benefits otherwise payable and expenses otherwise reimbursable to him under Section 3 through the last day of his actual employment by the Company. 

5.2. Termination at the Election of the Executive Without Good Reason. In the event the Executive elects to terminate his
employment pursuant to Section 4.5, the Company shall pay the Executive the compensation and benefits otherwise payable and expenses otherwise reimbursable to him under Section 3 through the last day of his actual employment by the
Company. Executive shall not be liable to the Company for any damages arising from or associated with the Company’s not having a Vice President, Clinical and Regulatory during any period following a termination by the Executive of his
employment and this Agreement pursuant to Section 4.5. 
 5.3. Termination for Death or Disability. If the
Executive’s employment is terminated by death or because of Disability pursuant to Section 4.4, in addition to any disability or life insurance benefits for which the Executive or the estate of the Executive may be eligible,

  
 -3-

 
the Company shall pay to the estate of the Executive or to the Executive, as the case may be, the compensation and benefits otherwise payable and expenses otherwise reimbursable to him under
Section 3 through the last day of his actual employment by the Company. In addition, if the Executive’s employment terminates as a result of his death, the Executive’s estate shall receive an amount equal to a pro rata payment of the
annual cash bonus for which he would have been eligible, less lawful deductions, within ten (10) calendar days following the effective date of the Release required by Section 5.6, but not later than ninety (90) days following
termination of employment. Notwithstanding the foregoing, if the ninetieth (90th) day following the Executive’s termination from employment occurs in the calendar year following the year of the Executive’s termination, then the
payment shall be made no earlier than January 1 of such subsequent calendar year. No other benefits are payable upon the Executive’s termination pursuant to Section 4.4. 

5.4. Termination Without Cause or for Good Reason and not during a Change of Control Period. The Executive shall not be
entitled to any severance related payments (other than those in paragraph (a) below) or benefits as a result of his termination Without Cause or termination for Good Reason unless notice of such termination is provided after the first
anniversary of the Effective Date (such anniversary date, the “Benefit Date”). Thereafter, if the Executive’s employment is terminated without Cause pursuant to Section 4.6, or for Good Reason pursuant to Section 4.2,
and such termination does not occur during a Change of Control Period, the Company shall: 
 (a) pay the Executive the
compensation and benefits otherwise payable and expenses otherwise reimbursable to him under Section 3 through the last day of his actual employment by the Company; 

(b) pay the Executive a lump sum payment equal to one (1) times his annualized base salary, less lawful
deductions, payable within ten (10) calendar days following the effective date of the Release required by Section 5.6 but not later than ninety (90) days following termination of employment. Notwithstanding the foregoing, if the
ninetieth (90th) day following the Executive’s
termination from employment occurs in the calendar year following the year of the Executive’s termination, then the payment shall be made no earlier than January 1 of such subsequent calendar year; 

(c) pay on behalf of the Executive, in accordance with the Company’s regular payroll practices, on a monthly basis an amount equal
to (i) one hundred (100%) percent of the Executive’s monthly health and dental COBRA premiums for the Executive and his dependents, if any, if the Executive properly elects to continue health and dental insurance under COBRA and
(ii) pay to the Executive on the first business day of each applicable month one hundred (100%) percent of the cost of the monthly premiums paid by the Company to the insurance companies for life insurance and disability insurance for the
Executive in the month preceding the Executive’s termination of employment, such payments under subsections (i) and (ii) to continue until the earlier of (x) twelve (12) months after the termination of the Executive’s
employment and (y) the last day of the first month that the Executive is eligible for other employer-sponsored health coverage. Notwithstanding the foregoing, to the extent such payments are reimbursement to the Executive of medical expenses
incurred by the Executive as 

  
 -4-

 
described in Reg. § 1.409A-1(b)(9)(v)(B), reimbursements may not be made beyond the period of time during which the Executive would be entitled (or would, but for such arrangement, be
entitled) to COBRA continuation coverage under a group health plan of the Company; 
 (d) pay the
Executive a lump sum payment in an amount equal to a pro rata payment of the Target Cash Bonus for which he was eligible, less lawful deductions; such payment shall be paid within ten (10) calendar days following the effective date of the
Release required by Section 5.6, but not later than ninety (90) days following termination of employment. Notwithstanding the foregoing, if the ninetieth (90th) day following the Executive’s termination from employment occurs in the calendar year following the year of
the Executive’s termination, then the payment shall be made no earlier than January 1 of such subsequent calendar year; and 
 (e) accelerate vesting of all of the Executive’s outstanding unvested stock options and restricted stock by one (1) year. 

5.5. Termination Without Cause or for Good Reason during a Change of Control Period. If the Executive’s employment is
terminated without Cause pursuant to Section 4.3, or for Good Reason pursuant to Section 4.3, and such termination occurs during a Change of Control Period, the Company shall: 

(a) pay the Executive the compensation and benefits otherwise payable and expenses otherwise reimbursable to him under Section 3
through the last day of his actual employment by the Company; 
 (b) pay the Executive a lump sum payment
equal to one (1) times his annualized base salary, less lawful deductions, payable within ten (10) calendar days following the effective date of the Release required by Section 5.6, but not later than ninety (90) days following
termination of employment. Notwithstanding the foregoing, if the ninetieth (90th) day following the Executive’s termination from employment occurs in the calendar year following the year of the Executive’s termination, then the payment shall be made no earlier than
January 1 of such subsequent calendar year; 
 (c) pay on behalf of the Executive, in accordance with the Company’s
regular payroll practices, on a monthly basis an amount equal to (a) one hundred (100%) percent of the Executive’s monthly health and dental COBRA premiums for the Executive and his dependents, if any, if the Executive properly elects
to continue health and dental insurance under COBRA and (b) pay to the Executive on the first business day of each applicable month one hundred (100%) percent of the cost of the monthly premiums paid by the Company to the insurance
companies for life insurance and disability insurance for the Executive in the month preceding the Executive’s termination of employment, such payments under subsections (a) and (b) to continue until the earlier of (x) twelve
(12) months after the termination of the Executive’s employment and (y) the last day of the first month that the Executive is eligible for other employer-sponsored health coverage. Notwithstanding the foregoing, to the extent such
payments are reimbursement to the Executive of medical expenses incurred by the Executive as described in Reg. § 1.409A-1(b)(9)(v)(B), reimbursements may not be made beyond the period of time during which the Executive would be entitled (or
would, but for such arrangement, be entitled) to COBRA continuation coverage under a group health plan of the Company; 

  
 -5-

 (d) pay the Executive a lump sum payment in an amount equal to a pro rata payment of the
Target Cash Bonus for which he was eligible, less lawful deductions; such payment shall be paid ten (10) calendar days following the effective date of the Release required by Section 5.6, but not later than ninety (90) days following
termination of employment. Notwithstanding the foregoing, if the ninetieth (90th) day following the Executive’s termination from employment occurs in the calendar year following the year of the Executive’s termination, then the
payment shall be made no earlier than January 1 of such subsequent calendar year; and 
 (e) accelerate vesting of one
hundred (100%) percent of all of the Executive’s outstanding unvested stock options and restricted stock. 
 5.6.
Conditions to Payment. 
 (a) Notwithstanding any provision of this Agreement to the contrary, the Company’s
obligation to provide the payments and benefits under Sections 5.3, 5.4, and 5.5 is conditioned upon the Executive’s, or the Executive’s estate’s, execution of a severance agreement and full release of all claims against the Company
and all affiliated persons and entities, drafted by and reasonably satisfactory to counsel for the Company (the “Release”), and the Executive’s compliance with Sections 7 and 8 of this Agreement. The Release shall include
clauses covering confidentiality, non-disparagement, cooperation, and non-admissions, among other terms, all in a form reasonably acceptable to the Company. The Executive, at his expense, may consult with legal counsel and may propose revisions to
the Release, which the Company agrees to consider in good faith. If the Executive chooses not to execute such a release or fails to comply with those Sections, then the Company’s obligation to compensate the Executive ceases on the effective
termination date except as to base salary up through the termination date. The Release shall be provided to the Executive within thirty (30) days of the Executive’s separation from service and the Executive must execute it within the time
period specified in the Release (which shall not be longer than forty-five (45) days from the date of receipt). Such Release shall not be effective until any applicable revocation period specified therein has expired. 

(b) Notwithstanding any provision of this Agreement to the contrary, the Company’s obligation to provide the payments and benefits
under Section 5.4 shall not arise until the Benefit Date and is expressly conditioned upon the Executive remaining an employee in good standing with the Company through the Benefit Date. 

6. Vesting of Stock Upon a Change of Control. One hundred (100%) percent of the Executive’s outstanding unvested
stock options and restricted stock will vest on a Change of Control (as defined in Section 20). 
 7.
Non-Compete. 
 7.1. During the Executive’s employment with the Company and for a period of one
(1) year following the cessation thereof, the Executive will not engage in any of the following on his own behalf or in any capacity on another’s behalf: 
 (a) engage in any business activity (or assist others to engage in any business activity) that directly competes with the Company; or 

  
 -6-

 (b) have any interest in any business that directly competes with the Company; or

 (c) be employed (or otherwise engaged) in (A) a management capacity, (B) other capacity providing the same or
similar services which the Executive provided to the Company, or (C) any capacity connected with competitive business activities, by any person or entity that engages in the same, similar or otherwise competitive business as the Company.

 The restrictions set forth in subparagraphs 7.1(a)–(c) shall apply in the following severable geographic areas: (i) the
Raleigh-Cary-Durham-Chapel Hill, NC metropolitan areas; (ii) any city, metropolitan area, county, state (or similar political subdivisions in foreign countries) in which the Company is located or does or, during the last twelve (12) months
of the Executive’s employment with the Company, did business; (iii) any city, metropolitan area, county, or state (or similar political subdivisions in foreign countries) in which the Executive’s services were provided, or for which
the Executive had responsibility, or in which the Executive worked on Company projects, during the last twelve (12) months of the Executive’s employment with the Company; or (iv) the entire United States of America and its
territories. 
 7.2. During the Executive’s employment with the Company and for a period of one (1) year following
the cessation thereof (whether voluntary or involuntary and regardless of the reason for, or party initiating, the termination), the Executive will not engage in any of the following on his own behalf or in any capacity on another’s behalf,
directly or indirectly: 
 (a) solicit, persuade, induce, encourage or attempt to solicit, persuade, induce or encourage any
person to leave his or her employment with the Company or to refrain from providing services to the Company; or 
 (b) induce
or attempt to induce (including, without limitation, by soliciting business from), or otherwise encourage or assist, any customer, client, or business relation of the Company with which the Executive had contact on behalf of the Company (i) to
cease doing business with the Company or reduce the level of business it conducts with the Company, or (ii) to purchase or promote any prescription pharmaceutical product that competes directly with the Company’s products for the treatment
of any indication for which the Company has received United States Food and Drug Administration (“FDA”) approval or for an indication which the Company’s products are being developed or may be developed. 

Upon cessation of the Executive’s employment with the Company, the Executive will sever all marketing and sales relationships with customers of the
Company and the Executive agrees that any attempt to retain these customers for his own or another’s benefit will be a material breach of this Agreement. 
 7.3. The Executive agrees that, if requested by the Company in writing, he will give notice to the Company of each new business activity he plans to undertake during the non-competition period, at least
ten (10) business days prior to beginning any such activity. The 

  
 -7-

 
notice shall state the name and address of the individual, corporation, association or other entity or organization (“Entity”) for whom such activity is undertaken and the
name of the Executive’s business relationship or position with the entity. The Executive further agrees to provide the Company with other pertinent information concerning such business activity as the Company may reasonably request in order to
determine the Executive’s continued compliance with his obligations under this Agreement. The Executive agrees that, if requested by the Company in writing, he will provide a copy of Sections 7 and 8 of this Agreement to all persons and
Entities with whom he seeks to be hired or do business before accepting employment or engagement with any of them. 
 7.4. If
any restriction set forth in this Section 7 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall
be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable. 
 7.5. The Executive acknowledges that the restrictions contained in this Section are necessary for the protection of the business and goodwill of the Company and in light of, among other things, the highly
competitive market in which the Company operates. The Executive agrees that any breach of this Section will cause the Company substantial and irreparable damage and therefore, in the event of any such breach, in addition to such other remedies which
may be available, the Company shall have the right to seek specific performance and injunctive relief without posting a bond. 

7.6. If the Executive violates the provisions of this Section 7, he shall continue to be held by the restrictions set forth in this
Section, until a period equal to the period of restriction has expired without any violation. 
 8. Proprietary
Information and Developments. 
 8.1. Proprietary Information. 

(a) The Executive agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature
concerning the Company’s business or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company. By way of illustration, but not limitation, Proprietary Information
may include inventions, products, processes, methods, techniques, formulas, compositions, compounds, projects, developments, plans, research data, clinical data, financial data, personnel data, computer programs, and customer and supplier lists. The
Executive will disclose Proprietary Information solely to employees, officers, and directors of the Company and only on a need-to-know basis and will use the same solely for purposes of performing the Executive’s duties and responsibilities on
behalf of Company as described in Section 2 hereof, unless otherwise permitted by prior written approval of an officer of the Company. Developments (defined in Section 8.2(a) below) shall constitute Proprietary Information of Company for
all purposes hereunder. 

  
 -8-

 (b) The Executive agrees that all files, letters, memoranda, reports, records, data,
sketches, drawings, laboratory notebooks, program listings, or other written, photographic, or other tangible material containing Proprietary Information, whether created by the Executive or others, which shall come into his custody or possession,
shall be and are the exclusive property of the Company to be used by the Executive only in the performance of his duties for the Company. 
 (c) The Executive agrees that his obligations set forth in paragraphs (a) and (b) above also extend to such types of information, know-how, records and tangible property of customers of the
Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Executive in the course of the Company’s business. 

8.2. Developments. 
 (a) The Executive will make full and prompt disclosure to the Company of all inventions, discoveries, processes, methods, developments, software, and works of authorship, whether or not patentable or
copyrightable, which are created, made, conceived or reduced to practice by the Executive or under his direction or jointly with others during his employment by the Company, whether or not during normal working hours or on the premises of the
Company (all of which, along with all improvements, modifications, and derivative works thereof and thereto and all proprietary know-how and other information associated therewith, are collectively referred to in this Agreement as
“Developments”). 
 (b) The Executive agrees to irrevocably and unconditionally assign, and does hereby
irrevocably and unconditionally assign, to the Company (or any person or entity designated by the Company) and to forever waive and never assert any and all of his right, title and interest in and to all Developments and all related patents,
patent applications, copyrights, copyright registration applications, and other intellectual property rights and moral rights associated therewith. The rights assigned to Company herein shall include, without limitation, the rights (i) to bring
claims and causes of action for damages and other relief by reason of all past and future infringements, misappropriations, or other violations of any and all rights under such Developments; (ii) to collect and enjoy damages, benefits, and
other remedies resulting therefrom; and (iii) to charge and collect royalties or other payments arising out of or relating to the grant of licenses or similar rights under any such Developments. 

(c) The Executive agrees to cooperate fully with the Company, both during and after his employment with the Company, with respect to the
prosecution, procurement, maintenance, enforcement and/or defense of patents, trademarks, copyrights, trade secrets and other means for protection of the Developments (both in the United States and foreign countries). The Executive shall sign all
papers, including, without limitation, copyright registration applications, patent applications, declarations, oaths, formal assignments, assignment of priority rights, and powers of attorney, which the Company may deem necessary or desirable in
order to protect its rights and interests in any Development. The Executive shall further execute and deliver all such instruments and take all other actions as in the opinion of the Company and its counsel shall be appropriate to vest in the
Company (or in such person as the Company may 

  
 -9-

 
specify) all right, title and interest in said Developments and any patents, trademarks, copyrights, trade secrets and other intellectual property rights associated therewith. The Executive shall
be entitled to reasonable compensation for all time devoted to such post-employment cooperation at a rate equal to three hundred ($300) dollars per hour. 
 (d) Whenever requested to do so by the Company, both during and after his employment with the Company, and at the expense of the Company, the Executive shall cooperate fully and assist the Company in the
defense or prosecution of any claims or actions now in existence or which may be brought in the future in connection with (i) any litigation commenced by the Company against third parties, (ii) any litigation commenced by a third party
against the Company and (iii) any administrative hearing or administrative proceeding involving the Company. The Executive’s full cooperation in connection with any claims, actions or administrative proceedings shall include, but not be
limited to, his being available to meet with the Company’s counsel to prepare for trial, discovery or an administrative hearing and to act as a witness when requested by the Company at reasonable times designated by the Company. The Executive
shall be entitled to reasonable compensation for all time devoted to such post-employment cooperation at a rate equal to three hundred ($300) dollars per hour. 
 (e) The Executive hereby irrevocably appoints the Company to be his attorney in fact and, in his name and on his behalf, to execute all such instruments and take all other actions and generally to use his
name for the purpose of providing to the Company the full benefit of the provisions of subsections 8.2(b) and 8.2(c). 
 (f)
The Executive hereby waives and quitclaims to the Company any and all claims, of any nature, which the Executive now or may hereafter have for infringement, misappropriation, or other violation of any Development assigned hereunder to the Company.

 (g) The Executive acknowledges and agrees that all original works of authorship which are created by the Executive (solely
or jointly with others) within the scope of the Executive’s employment and which are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act (17 U.S.C. Section 101).

 (h) The Executive represents and warrants that to the extent applicable, the Executive has provided to the Company a list
entitled “List of Inventions,” that a true and complete list of all inventions, discoveries, methods, processes, developments, software, and works of authorship, whether or not patentable or copyrightable, which were created, made,
conceived or reduced to practice by the Executive, whether solely or jointly with others, prior to his employment by the Company (collectively, “Inventions”). Any improvements to or derivative works of any such Inventions, whether
or not patentable or copyrightable and whether or not reduced to practice, conceived or created after commencement of the Executive’s employment by the Company shall constitute Developments for all purposes hereunder to the extent arising out
of or relating to any use of or other reliance on any Proprietary Information by or on behalf of the Executive. 
 8.3.
Other Agreements. Other than as previously disclosed to the Company by the Executive in writing, the Executive hereby represents that he is not bound by the terms of any agreement with any previous employer or other party to refrain from
using or disclosing any 

  
 -10-

 
trade secret or confidential or proprietary information in the course of his employment with the Company or to refrain from competing, directly or indirectly, with the business of such previous
employer or any other party. The Executive further represents that his performance of all the terms of this Agreement and as an executive officer of the Company does not and will not breach any agreement to keep in confidence proprietary
information, knowledge or data acquired by him in confidence or in trust prior to his employment with the Company. 
 9.
Other Severance Arrangements. The benefits under this Agreement will be provided in lieu of benefits under any severance plan of the Company or under the Executive’s offer letter. The Executive acknowledges and agrees that the
acceleration of vesting of stock options and restricted stock under this Agreement is in lieu of any acceleration of vesting of stock options and restricted stock upon a change of control under the Company’s current and any future stock option
plans, including, but not limited to, the Company’s 2000 Equity Incentive Plan, 2003 Stock Incentive Plan, 2004 Stock Incentive Plan, the Cornerstone BioPharma Holdings, Inc. 2005 Stock Option Plan, and the Cornerstone BioPharma Holdings, Inc.
2005 Stock Incentive Plan, each as amended from time to time. 
 10. Mitigation. The Executive has no obligation
to mitigate amounts payable under this Agreement by seeking other employment. 
 11. Notices. All notices required
or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, if to the Company, at its principal office
addressed to the attention of Craig Collard, CEO, and if to the Executive, at the address specified in his most recently submitted IRS Form W-4, or at such other address or addresses as either party shall designate to the other in accordance with
this Section 11. 
 12. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall
include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 
 13. Entire Agreement. This Agreement constitutes the entire understanding between the parties hereto with respect to the subject matter hereof, and this Agreement supersedes and renders null
and void any and all prior oral or written agreements, understandings or commitments pertaining to the subject matter hereof. To the extent this Agreement is inconsistent or conflicts with any other agreement entered into between the Executive and
the Company, including any option or restricted stock award agreements, this Agreement shall control. 
 14.
Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive. 
 15. Governing Law. This Agreement shall be interpreted and enforced in accordance with the laws of the State of North Carolina without regard to conflict of laws provisions. 

  
 -11-

 16. Successors and Assigns. This Agreement shall be binding upon and inure to
the benefit of both parties and their respective successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the
Executive are personal and shall not be assigned by the Executive. 
 17. Dispute Resolution. Any claim or
controversy arising out of or relating to this Agreement, or any breach thereof, or otherwise arising out of or relating to the Executive’s employment, compensation and benefits with the Company or the termination thereof, including any claim
for discrimination under any local, state or federal employment discrimination law, except as specifically excluded herein, shall be brought in only in a court of the State of North Carolina (or, if appropriate, a federal court located within the
State of North Carolina), and the Company and the Executive each consents to the jurisdiction of such a court. Both the Company and the Executive expressly waive any right that any party either has or may have to a jury trial of any dispute
arising out of or in any way related to the Executive’s employment with or termination from the Company. The Executive expressly acknowledges and agrees that he hereby waives any right to claim or recover punitive damages. 

18. Acknowledgment. THE EXECUTIVE ACKNOWLEDGES THAT HE HAS HAD A REASONABLE PERIOD SUFFICIENT TO STUDY, UNDERSTAND AND CONSIDER
THIS AGREEMENT, THAT HE HAS HAD AN OPPORTUNITY TO CONSULT WITH LEGAL COUNSEL OF HIS CHOICE, THAT HE HAS READ THIS AGREEMENT AND UNDERSTANDS ALL OF ITS TERMS, THAT HE IS ENTERING INTO AND SIGNING THIS AGREEMENT KNOWINGLY AND VOLUNTARILY, AND THAT IN
DOING SO HE IS NOT RELYING UPON ANY STATEMENTS OR REPRESENTATIONS BY THE COMPANY OR ITS AGENTS. 
 19.
Miscellaneous. 
 19.1. No delay or omission by the Company in exercising any right under this Agreement shall
operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 

19.2. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the
scope or substance of any section of this Agreement. 
 19.3. In case any provision of this Agreement shall be invalid, illegal
or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 
 19.4. Nothing in this Agreement should be construed to create a trust or to establish or evidence the Executive’s claim of any right to payment other than as an unsecured general creditor with
respect to any payment to which the Executive may be entitled. 

  
 -12-

 19.5. The provisions of Sections 5, 7, 8, 15, 17 and 21 shall survive the termination of
this Agreement. 
 19.6. Upon termination of the Executive’s employment by the Company for any reason whatsoever whether
voluntarily or involuntarily, or at any other time upon the Company’s request, the Executive agrees to promptly return to the possession of the Company any materials or copies thereof, in hard copy or electronically, containing and/or
pertaining to Proprietary Information relating to the Company or any of its subsidiaries or affiliates and shall not take any material or copies thereof from the possession of the Company, or destroy any such materials. In addition, the Executive
shall also return to the Company all Company property and equipment in the Executive’s possession or control, including but not limited to, all documents, product samples, tapes, notes, computer files, equipment, phone, facsimile, printer,
computer, physician lists, employee lists, lab notebooks, files, computer equipment, security badges, telephone calling cards, credit cards, and other information or materials (and all copies) which contain confidential, proprietary or non-public
information of the Company. The Executive further agrees to leave intact all electronic Company documents on the Company’s servers or computers, including those which the Executive developed or helped develop during the Executive’s
employment. The Executive further agrees to promptly return or make available to the Company or its agents any motor vehicle provided to the Executive by the Company. 
 20. Definitions. 
 20.1. For purposes of this Agreement,
“beneficial ownership” shall have the meaning set forth in Rule 13d-3 promulgated under the Exchange Act, and “beneficially own(s)” and “beneficially owned” shall have correlative meanings.

 20.2. For the purposes of this Agreement, “Cause” for termination shall be deemed to exist upon
(a) the Executive’s use of alcohol or narcotics which proximately results in the willful material breach or habitual willful neglect of the Executive’s duties under this Agreement; (b) the Executive’s criminal conviction of
fraud, embezzlement, misappropriation of assets, or the Executive’s conviction of any felony or crime of moral turpitude, but in no event traffic or similar violations; (c) any act of the Executive constituting willful misconduct which is
materially detrimental to the Company’s best interests, including but not limited to misappropriation of, or intentional damage to, the funds, property or business of the Company; (d) except with regard to violation of Company policies
prohibiting harassment or discrimination, the Executive’s material violation of the Company’s policies if such violations are not cured or ended within thirty (30) days after notice thereof by the Company specifying the nature of such
material violation; (e) the Executive’s material violations of the Company’s policies prohibiting harassment or discrimination; or (f) the Executive’s willful Material Breach (as defined below) of this Agreement, if such
willful Material Breach is not cured by the Executive within thirty (30) days after the Company’s written notice thereof specifying the nature of such willful Material Breach. “Material Breach” shall mean (x) the
substantial and continual willful nonperformance of the Executive’s material duties under this Agreement resulting from the Executive’s gross negligence or willful misconduct which the Board reasonably determines has resulted in material
injury to the Company or (y) the breach of Section 7 or Section 8 of this Agreement. 

  
 -13-

 20.3. For purposes of this Agreement, a “Change of Control” shall mean:

 (a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the
Exchange Act (as defined below)) (a “Person”), other than Chiesi Farmaceutici SpA or any of its affiliates, of beneficial ownership of any capital stock of the Company if prior to such acquisition such Person did not, and after
such acquisition such Person does, beneficially own fifty (50%) percent or more of the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding
Company Voting Securities”); or 
 (b) such time as the Continuing Directors (as defined below) do not constitute a
majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term “Continuing Director” means at any date a member of the Board (x) who was a member of the Board on the
date of the initial adoption of the Employment Agreement by the Board or (y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election
or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause
(y) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or
on behalf of a person other than the Board; or 
 (c) the consummation of a merger, consolidation, reorganization,
recapitalization or share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company (a “Business Combination”), unless, immediately following such Business Combination,
each of the following two conditions is satisfied: (x) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Voting Securities immediately prior to such Business Combination
beneficially own, directly or indirectly, more than fifty (50%) percent of the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring
corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company’s assets either directly or through one or more
subsidiaries) (such resulting or acquiring corporation is referred to herein as the “Acquiring Corporation”) in substantially the same proportions as their ownership of the Outstanding Company Voting Securities immediately prior to
such Business Combination and (y) no Person (excluding any executive benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, fifty
(50%) percent or more of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business
Combination); or 

  
 -14-

 (d) the liquidation or dissolution of the Company. 

Notwithstanding this Section 20.3, any change in ownership of the outstanding capital stock of the Company that results from the acquisition of
additional shares by Chiesi Farmaceutici SpA or any of its affiliates (including any “going private” transaction whereby Chiesi Farmaceutici SpA would acquire all of the outstanding capital stock of the Company not then owned by them),or
changes in Board composition resulting from the exercise by Chiesi Farmaceutici SpA and its affiliates of voting power as majority stockholder(s) of the Company, shall not constitute a “Change of Control” within the context of this
Agreement. 
 20.4. For purposes of this Agreement, a “Change of Control Period” shall consist of the period
from three (3) months before until three (3) months after the date on which a Change of Control occurs. 
 20.5. As
used in this Agreement, the term “Disability” means, with respect to the Executive, that the Executive is unable to perform the essential functions of his position with a reasonable accommodation if necessary by reason of any
medically determinable physical or mental impairment. A determination of Disability shall be agreed upon by a physician satisfactory to the Executive and a physician selected by the Company, provided that if these physicians do not
agree, the Executive and the Company shall each select a physician and these two together shall select a third physician, whose determination as to Disability shall be binding on all parties. 

20.6. As used in this Agreement, the term “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

 20.7. For purposes of this Agreement, “Good Reason” shall be deemed to exist upon (a) any material
reduction in the annual base compensation payable to the Executive (but exclusive of any Target Cash Bonus, annual equity award or other similar cash bonus or equity plans for this purpose); (b) the relocation of the place of business at which
the Executive is principally located to a location that is greater than thirty (30) miles from its current location; (c) the failure of the Company to comply with a material term of this Agreement; (d) a material reduction in the
Executive’s level of responsibility to that which is not consistent with the position held by the Executive, as defined in Section 2 herein, so long as notice of the Good Reason condition is given within thirty (30) days of the
condition’s initial existence, the Company is given thirty (30) days to remedy the condition, and the termination from employment occurs within ninety (90) days following the initial existence of one or more Good Reason conditions;
(e) the Company’s shares cease to be publicly traded at a time when Chiesi Farmaceutici SpA and its affiliates do not own at least fifty (50%) percent of the outstanding shares of the Company; or (f) the Company’s shares are
delisted from or by Nasdaq at a time when Chiesi Farmaceutici SpA and its affiliates do not own at least fifty (50%) percent of the outstanding shares of the Company. By way of clarification, neither (I) any change in ownership of the
outstanding capital stock of the Company that results from the acquisition of shares by Chiesi Farmaceutici SpA or any of its affiliates, including but not limited to, the fact that the Company is no longer registered pursuant to
Section 12 of the Securities Act of 1933, as amended, nor (II) the Company’s action to seek suspension of its reporting obligations under Section 15(d) of the Exchange Act (i.e., “going dark”), shall of itself constitute a
“Good Reason” within the context of this Agreement. 

  
 -15-

 20.8. For purposes of this Agreement, “pro rata
payment” shall be deemed to mean the calculation of a payment by the Company based on the proportion of the calendar year completed, based on the nearest whole number of months of the Executive’s employment (for illustrative purposes
only, if the Executive was terminated without Cause by the Company on April 13th of a given year, the Executive would be entitled to 1/4 of his Target Cash Bonus for such year under Section 5.4(d). 
 21. Non-Disparagement. The Executive understands and agrees that as a condition to him of the monetary consideration provided in connection with this Agreement, during the term of the
Agreement and after the termination of his employment with the Company for any reason, he shall not make any false, disparaging or derogatory statements in public or private to any person or media outlet regarding the Company or any of its
directors, officers, employees, agents, or representatives or the Company’s business affairs and financial condition. The Company understands and agrees that during the term of the Agreement and after the termination of the Executive’s
employment with the Company for any reason, the Company shall not make any false, disparaging or derogatory statements in public or private to any person or media outlet regarding the Executive. Nothing in this Section shall prohibit either Party
from communicating or testifying truthfully (i) to the extent required or protected by law, (ii) to any federal, state, or local governmental agency, or (iii) in response to a subpoena to testify issued by a court of competent
jurisdiction. 
 22. Section 409A. 
 22.1. Parties’ Intent. The parties intend that the provisions of this Agreement comply with the provisions of Section 409A and all provisions of this Agreement shall be construed in a
manner consistent with the requirements for avoiding taxes or penalties under Section 409A. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause the Executive to incur any
additional tax or interest under Section 409A, the Company shall, upon the specific request of the Executive, use its reasonable business efforts to in good faith reform such provision to comply with Section 409A; provided, that to the
maximum extent practicable, the original intent and economic benefit to the Executive and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any changes that could create any additional
economic cost or loss of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plan or program in which the Executive participates to bring it in compliance with Section 409A. Notwithstanding the
foregoing, the Company shall have no liability with regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith. 

22.2. Separation from Service. A termination of employment shall not be deemed to have occurred for purposes of any provision of
this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination also constitutes a “Separation from Service” within the meaning of Section 409A and, for
purposes of any such provision of this Agreement, references to a “termination,” “termination of employment,” “separation from service” or like terms shall mean Separation from Service. 

  
 -16-

 22.3. Separate Payments. Each installment payment required under this Agreement
shall be considered a separate payment for purposes of Section 409A. 
 22.4. Delayed Distribution to Key
Employees. If the Company determines in accordance with Sections 409A and 416(i) of the Code and the regulations promulgated thereunder, in the Company’s sole discretion, that the Executive is a Key Employee of the Company on the date the
Executive’s employment with the Company terminates and that a delay in benefits provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i), then any severance payments and any continuation of benefits or
reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be delayed for a period of six (6) months following the date of termination of the Executive’s employment (the “409A
Delay Period”). In such event, any severance payments and the cost of any continuation of benefits provided under this Agreement that would otherwise be due and payable to the Executive during the 409A Delay Period shall be paid to the
Executive in a lump sum cash amount in the month following the end of the 409A Delay Period. For purposes of this Agreement, “Key Employee” shall mean an employee who, on an Identification Date (“Identification
Date” shall mean each December 31) is a key employee as defined in Section 416(i) of the Code without regard to paragraph (5) thereof. If the Executive is identified as a Key Employee on an Identification Date, then the
Executive shall be considered a Key Employee for purposes of this Agreement during the period beginning on the April 1st Date following the Identification Date and ending on the following March 31. 

23. Parachutes. If all, or any portion, of the payments provided under this Agreement, either alone or together with other
payments and benefits which the Executive receives or is entitled to receive from the Company or an affiliate, would constitute an excess “parachute payment” within the meaning of Section 280G of the Code, the payments and benefits
provided under this Agreement shall be reduced to the extent necessary so that no portion thereof shall fail to be tax-deductible under Section 280G of the Code. 
 [Remainder of this page is intentionally left blank] 

  
 -17-

 SIGNATURE PAGE TO EXECUTIVE EMPLOYMENT AGREEMENT 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth above. 

 

					
	CORNERSTONE THERAPEUTICS INC.
		
	By:	 	 /s/ Craig A. Collard

		 	Name:	 	Craig A. Collard
		 	Title:	 	Chief Executive Officer
	
	EXECUTIVE
		
	By:	 	 /s/ Andreas Maetzel

	Andreas Maetzel, M.D., M.Sc., Ph.D.

 Appendix A 

 

	1.	Shares of restricted stock awarded pursuant to Section 3.3 will be subject to the terms of the Company’s Restricted Stock Agreement and will vest over 4 years
as follows: 

 Twenty-five (25%) percent of the total award will vest on each of the first four
(4) anniversaries of the Effective Date; 
 [The following provision will be in the Restricted Stock Agreement which will
be provided as soon as the same is approved by the Board : If there is a “Buy-Out Transaction” (meaning (i) a transaction or series of transactions whereby a Chiesi entity ultimately acquires all or substantially all of the Company
stock, or (ii) a transaction that under the Plan would constitute a Change of Control and which the Board, or the Compensation Committee thereof, determines in its discretion will be treated as a Buy Out Transaction and so notifies the
Executive) any Restricted Shares then unvested would be converted into the right to receive an amount equal to the consideration payable per share in the Buy-Out Transaction, including any right to receive earn out or additional consideration
based on future contingencies, which amount shall be retained as “Restricted Cash” and paid out in accordance with the original vesting schedule. If after the Buy Out Transaction the Executive is involuntarily
terminated, other than for Cause, or if the Executive is constructively terminated as a result of his compensation, authority, duties, or responsibilities being materially reduced, or of a material change in his location of employment , all
Restricted Cash would be payable in a lump sum within ten (10) calendar days following the date of termination] 
  

	2.	Options to acquire common stock awarded pursuant to Section 3.3 will be subject to the terms of the Company’s Stock Option Agreement and will vest over four
(4) years as follows: 

  

	 	a.	Twenty-five (25%) percent of the total award will vest on the first anniversary of the Effective Date; 

 

	 	b.	An additional two point nine (2.09%) percent of the total award will vest at the beginning of each of the next thirty-five months following the first anniversary
of the Effective Date and the remainder of the total award will vest on the fourth anniversary of the Effective Date. 

 All
rights of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all shares for which the option is
vested until the earlier of the final exercise date or the termination of the option. 

  
 -2-EX-10.2

 Exhibit 10.2 
 Corrected and Restated 
 LICENSE AND DISTRIBUTION AGREEMENT 

Parties 
 This License
and Distribution Agreement (this “Agreement”) corrects and restates the License and Distribution Agreement effective May 9, 2013 (the “Effective Date”) by and between Digestive Care, Inc., a Pennsylvania corporation, having
a place of business at 1120 Win Drive, Bethlehem, PA 18017 (“DCI”) and Cornerstone Therapeutics Inc., a Delaware corporation (“CRTX”), having a place of business at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518.

 Recitals 

WHEREAS, DCI is engaged in the manufacture, promotion and sale of the products listed on Exhibit A to this Agreement (the “Products”),
which are indicated for the treatment of exocrine pancreatic insufficiency (“EPI”) due to Cystic Fibrosis and other conditions (“CF”); and 
 WHEREAS, CRTX has invested substantial resources in developing a direct sales force which specializes in the promotion and sale of pharmaceutical products to specialty pharmacies, group purchasing
organizations and other payors whose primary purpose in purchasing the Products is treatment of CF and to prescribers that are affiliated with hospitals, including prescribers that specialize in treating patients with CF; 

WHEREAS, DCI desires to grant CRTX the exclusive right to promote, sell and distribute the Products in the Territory (as defined in
Section 1(d)) to specialty pharmacies and to prescribers that specialize in treating patients with CF, and CRTX desires to be granted such exclusive right; 
 WHEREAS, CRTX and DCI intend to split the net sales revenue derived from the sale of the Products in the CF Market (as defined in Section 7(b)) in the ratio of [***], with CRTX paying to DCI
as a Revenue Split [***] of the net sales revenue it derives from sales of the Products attributable to the CF Market in the Territory (the “Revenue Split”), and DCI paying to CRTX as a co-promotion
fee [***] of the net sales that DCI derives from sales of the Product attributable to the CF Market in the Territory (the “Copromotion Revenue”); and 
 WHEREAS, CRTX and DCI recognize that CRTX’s activities under this Agreement may result in sales that are not attributable to the CF Market, and DCI’s activities may result in sales that
are attributable to the CF Market, and that the financial arrangements under this Agreement are intended to allocate the profit from such sales in a manner consistent with the intentions of the Parties. 

 
 [***] Confidential portions of the
exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

 Corrected and Restated 
  

 NOW, THEREFORE, in consideration of the foregoing and the covenants contained in this Agreement,
DCI and CRTX (each a “Party” and collectively, the “Parties”) intending to be legally bound hereby agree as follows: 
 When
used in this Agreement, capitalized terms have the defined meanings ascribed to them in the text of the Agreement. Exhibit B to this Agreement identifies the section of the Agreement in which each such term is defined. 

1. License Grant. 
  

	 	(a)	Grant of Rights. During the term of this Agreement, and subject to and in accordance with its terms and conditions, DCI hereby grants to CRTX and CRTX hereby
accepts the sole and exclusive right and license to promote, market, sell and distribute the Products in the Territory (i) to prescribers that specialize in treating patients with CF, including physicians and physician’s assistants and
nurse practitioners who are authorized to write prescriptions, (ii) to specialty pharmacies that fill prescriptions exclusively for patients with CF and (iii) to group purchasing organizations (“GPOs”) and other payors that
purchase the Products exclusively for use in the CF Market. The parties referred to in clauses (i) through (iii) of this Section 1(a) shall be collectively referred to as “Target Customers”. CRTX shall have the sole and
exclusive right and responsibility to negotiate agreements with Target Customers with respect to purchase of the Products. DCI retains all rights to promote, market, sell and distribute the Products in the Territory other than in relation to the CF
Market and Target Customers. Consequently, the Parties do not expect to compete with each other for the sales of the Products in the Territory. 

  

	 	(b)	New Products. In the event DCI develops a product for the CF Market (including any products which may in the future be developed as alternatives, substitutes,
improvements or successors to the Products) which requires a New Drug Application or an additional SKU requiring a supplemental New Drug Application, and such product is not already listed on Exhibit A, CRTX shall have the right of first refusal to
financially and/or otherwise participate in the development of such product by sharing the costs of such development on a basis to be negotiated in good faith. Upon conclusion of such negotiation any such product in development shall be considered a
Product for purposes of this Agreement. 

  

	 	(c)	Exclusivity. The license granted under this Agreement is limited in scope and shall be exclusive to CRTX, and the Parties shall structure all of their activities
strictly in compliance with such limitations and exclusivity. Accordingly, DCI agrees that that it will not knowingly promote, market, sell or distribute the Products in the Territory to Target Customers. 

  
 Page 2 of 74

 Corrected and Restated 
  

	 	(d)	Territory. The territory shall be the United States, which includes the fifty (50) states and the District of Columbia and the territories, possessions and
commonwealths of the United States (the “Territory”). 

  

	 	(e)	Non-Compete. CRTX agrees that it will not, for the term of this Agreement, and except as permitted by this Agreement, manufacture, promote, market, sell or
distribute in the Territory any pancreatic enzyme product that is indicated for the treatment of patients with CF, other than the Products. DCI agrees that it will not, except after offering CRTX the right of first refusal as provided in
Section 1(b) above, and that right having not been exercised by CRTX, for the term of this Agreement, engage in any activities in support of the promotion, marketing, sale or distribution of any buffered or non-buffered pancreatic enzyme or any
buffering product that could be marketed for use in combination with pancreatic enzymes to treat exocrine pancreatic insufficiency which would compete with the Products in the CF Market. 

 

	 	(f)	Non-solicitation. During the term of this Agreement and for a period of one (1) year thereafter, neither Party shall solicit or cause any other Party to
solicit the employment of any employee of the other Party that is at such time working for the other Party. 

  

	 	(g)	Subcontractors. CRTX shall have the right to appoint agents or co-promoters, at its own cost, to promote and market the Products under the terms of this
Agreement or to satisfy its obligations under this Agreement, with the prior written consent of DCI, which consent shall not be unreasonably withheld, delayed or conditioned. 

 

	 	(h)	Trademarks. During the term of this Agreement, DCI hereby grants CRTX the right and license to use the trademark “Pertzye®” and any other
trademarks and trade names belonging to DCI which relate to the Products (collectively, the “Trademarks”) for the purpose of promoting the Products. CRTX may, with the prior written consent of DCI, which consent shall not be unreasonably
withheld, create new slogans, trade dress or logos for use alone or in conjunction with the Trademarks, but shall not otherwise alter, modify or otherwise change the Trademarks. CRTX may also use its own name and logo in connection with CRTX’s
activities under this Agreement, provided that the manner of such use has first been approved by the Steering Committee (as defined in Section 2(a)). Nothing in this limited grant of rights shall imply that either Party acquires, nor will it
acquire, any further rights whatsoever in or to the trademarks or trade names of the other Party. All goodwill arising from use of a Party’s trademarks shall inure solely to the Party that owns the applicable trademarks.

 2. Steering Committee. 
  

	 	(a)	 Committee Responsibilities. A joint committee (the “Steering Committee”) shall be responsible for defining plans and strategies,
including remedial plans and 

  
 Page 3 of 74

 Corrected and Restated 
  

	 	
strategies, intended to maximize Net Sales (as defined in Section 7(a)) of the Products in the CF Market. To this end, various specific roles and decisions under this Agreement shall be
assigned to the Steering Committee. 

  

	 	(b)	Make Up of Steering Committee. The Steering Committee will be formed by two (2) representatives of each Party, and in each case one (1) of such
representatives shall be appointed as a co-chair of the Steering Committee. The co-chairs of the Steering Committee shall be the only voting members of the Steering Committee and shall be of the rank of Vice-President or above in their respective
organizations. The co-chairs of the Steering Committee may request the input or attendance of others at any Steering Committee meeting, as appropriate with consideration given to the confidential or proprietary nature of any information to be
discussed at such meeting. Both Parties recognize that their respective co-chairs may need to obtain guidance and authority from their respective Boards of Directors and/or Chief Executive Officers prior to some decisions, actions, or ballots of the
Steering Committee. 

  

	 	(c)	Process of the Steering Committee. The Steering Committee will meet as often as necessary but no less often than once in each calendar quarter, with such
quarterly meetings to occur between fifty (50) and sixty-five (65) days after the end of the preceding calendar quarter. A non-regular meeting of the Steering Committee can be called by either co-chair of the Steering Committee at any time
upon reasonable notice to the other Steering Committee members. Such notice will not be less than twenty-four (24) hours, unless such minimum notice is waived by both Co-Chairs and will contain the time, place, and the subject matter or
objective of the non-regular meeting. The Steering Committee shall be responsible for reviewing each of the matters referred to it under this Agreement, including for illustration purposes those matters referenced in Exhibit C hereto. Meetings may
be held in person or by video or telephone conference, except that, unless otherwise agreed, at least two (2) meetings each year shall be attended in person, one (1) at the premises of each Party. Each Party shall pay their own costs for
attending each meeting. 

  

	 	(d)	Decisions of the Steering Committee. Decisions of the Steering Committee shall be made by the unanimous vote of the
co-chairs and shall be reflected in written minutes of each meeting. CRTX’s co-chair shall be responsible for preparing all minutes of the meetings, and such minutes shall be circulated to DCI’s
Steering Committee Members, Board of Directors and/or Chief Executive Officer after each meeting for review. Minutes are not final until they have been approved by the co-chairs of the Steering Committee. A quorum of both co-chairs is required in
order to take any vote or make any decision within the purview of the Steering Committee. 

  

	 	(e)	 Lack of Unanimity. Any proposed action on which the co-chairs of the Steering Committee are unable to unanimously agree shall not be taken. If
not taking such action inhibits either Party from performing its obligations under this 

  
 Page 4 of 74

 Corrected and Restated 
  

	 	
Agreement, the Chief Executives of the Parties shall negotiate in good faith for a period of up to thirty (30) days to reach a reasonable solution, after which period any unresolved dispute
shall be subject to the dispute resolution and arbitration procedures set forth in Section 17. 

  

	 	(f)	Right to Inspect. Either Party may request the opportunity to inspect any information presented by the other Party to the Steering Committee, and the Party upon
whom a request for inspection is made shall arrange a mutually convenient time for such inspection, which shall be within normal business hours, shall be at the inspected Party’s place of business, shall not exceed three (3) days in
duration and shall be entirely at the inspecting Party’s expense. 

 3. CRTX Obligations - Promotion of the Products.

  

	 	(a)	Sales Force. CRTX will, at its own expense, on or before March 31, 2014, ensure that at least [***] full time equivalent employees (“FTEs”) are
dedicated to the promotion of products to Target Customers in the Territory (the “CF Sales Force”). CRTX shall have the option of adding additional FTEs to the CF Sales Force at its own expense. [***]. 

 

	 	(b)	Training. CRTX will ensure that the CF Sales Force is trained in the promotion and sale of the Products in the Territory in the CF Market using materials
provided by DCI or prepared by CRTX’s Promotional Review Board and approved by DCI, which approval shall not be unreasonably withheld, delayed or conditioned. CRTX shall complete such training for the initial CF Sales Force within ninety
(90) days of the execution of this Agreement. DCI shall, at CRTX expense, cooperate with and contribute to such training. All other direct costs related to the training of the CF Sales Force shall be borne by CRTX. 

 

	 	(c)	Promotion. CRTX shall use all reasonable efforts to promote the sales of the Products in the Territory in the CF Market by detailing the Target Customers. CRTX
shall promote the Products in a manner that is consistent with the indications for which the Products are approved by the U.S. Food and Drug Administration (“FDA”), all applicable legal requirements and the standards of professional
conduct and diligence that CRTX applies in the promotion of its own products. 

  

[***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

  
 Page 5 of 74

 Corrected and Restated 
  

	 	(d)	Promotional Materials. DCI shall provide to CRTX all existing stocks of promotional materials, exclusively used in the CF Market, free of charge. DCI shall own
all right, title and interest in and to such promotional materials, but CRTX shall have the right to distribute, reprint and use the promotional materials for promotion and detailing of the Products in accordance with the terms of this Agreement.
CRTX shall also have the right to amend the promotional materials provided to it by DCI, provided, however, that any change or development to any promotional materials, or any new promotional materials, will require the approval of CRTX’s
Promotional Review Board and DCI, which approval shall not be unreasonably withheld, delayed or conditioned. 

  

	 	(e)	Promotional Spend. CRTX shall invest a total of [***], the “Committed Promotional Spend”) in promotion and marketing of the Products in each of the
first [***], twelve (12) month periods beginning with the first calendar quarter date following the Effective Date (each period a “Promotion Year”, with the first such period including the time, if any, between the Effective Date and
the first calendar quarter date following the Effective Date). Within forty-five (45) days following the end of each Promotion Year, CRTX shall provide to DCI a reasonably detailed accounting of CRTX’s promotional investment during such
Promotion Year. CRTX must spend [***] in the first Promotion Year. In subsequent Promotions Years, a minimum of [***] must be spent in each Promotion Year. If in any Promotion Year, CRTX shall not have satisfied the Committed Promotional Spend
requirement, then CRTX shall incur or otherwise make promotional investments in the immediately following Promotion Year in an amount equal to at least the Committed Promotional Spend for such Promotion Year plus the amount of the Committed
Promotional Spend from the immediately prior Promotion Year that was not incurred or made. No breach of this subsection shall have occurred unless CRTX fails to satisfy the Committed Promotional Spend requirement for two (2) consecutive years.

  

	 	(f)	Make Up of Promotional Spend. Items included within the Committed Promotional Spend [***]. 

 

	 	(g)	Sample Ordering. CRTX shall order samples according to the procedure and with the lead times and payment terms as the Parties may agree (see Exhibit P), and
shall track its distribution of samples according to the requirements of and in compliance with the Prescription Drug Marketing Act (the “PDMA”). CRTX will provide reports to DCI in a format to enable DCI to report to FDA.

  

	 	(h)	Formulary. CRTX will use its best commercial efforts to pursue the inclusion and improvement of the position of the Products in insurance formularies, and any
Government Program (including Medicare and Medicaid) formularies, and shall keep DCI, and the Steering Committee, informed of the proposed terms of any such inclusion or improvement. 

 
  
 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

  
 Page 6 of 74

 Corrected and Restated 
  

 4. CRTX Obligations - Support for the Products. 

 

	 	(a)	Customer Service. CRTX shall establish a call center to manage and respond to customer inquiries relating to the supply and use of the Products in the CF Market.
The call center staff shall at all times have access to personnel with at least a Bachelor’s level degree in nursing, pharmacy, or equivalent medical qualifications. CRTX will refer to DCI all inquiries relating to the supply and use of the
Products outside the CF Market. 

  

	 	(b)	Information Collection. CRTX will be responsible for collecting information pertaining to customer inquiries as required by the appropriate Code of Federal
Regulations. CRTX shall submit all inquiries constituting Complaints under the Quality Agreement to DCI using the form attached as Exhibit D to this Agreement. All such information will be made available to DCI as soon as possible but in no case
later than seventy-two (72) hours after receipt by CRTX, or at such earlier time as may be appropriate under applicable regulations. 

  

	 	(c)	Reporting Obligations. As between the Parties, DCI shall be responsible for all regulatory reporting obligations, including the timely reporting of Complaints to
appropriate regulatory authorities in accordance with applicable legal requirements. 

  

	 	(d)	Forecasting. CRTX shall provide to the Steering Committee a rolling twelve (12) month forecast of commercial product usage, anticipated prescription demand
and sample usage in the CF Market. Such forecast shall be updated and submitted quarterly. 

  

	 	(e)	Reports. Within 45 (forty-five) days of the end of each calendar quarter, CRTX shall submit to the Steering Committee a report setting out all the items listed
on Exhibit E and all information in CRTX’s possession that bears on the calculation of Net Sales in the CF Market (the “CRTX Quarterly Report”). 

 5. DCI Obligations 
  

	 	(a)	 Manufacture of the Products. Subject to Section 5(b), DCI shall be solely responsible for the timely manufacture of the Products in
sufficient quantities to meet forecast demand, and shall ensure that it, or its contract manufacturer, maintains all necessary quality controls, and that the Products are manufactured in accordance with Current Good Manufacturing Practices
(“cGMP”), are 

  
 Page 7 of 74

 Corrected and Restated 
  

	 	
correctly labeled and, at the time of release, meet all Product specifications and other terms of a Quality Agreement substantially in the form attached to this Agreement as Exhibit F (the
“Quality Agreement”). The Parties will enter into a separate Quality Agreement in a mutually acceptable form, setting out the protocols that they will follow to ensure that only conforming Products are distributed and sold.

  

	 	(b)	Manufacturing Capacity; Supply Failure. 

  

	 	(i)	Build Out of Manufacturing Facility. In the event that demand for Products exceeds or is reasonably expected to exceed [***], DCI shall take such steps as may be
necessary to expand its manufacturing capacity (whether its own or a contract manufacturer’s); provided, however, that the Parties shall negotiate in good faith with respect to sharing the costs of such expansion [***]. If this situation
eventuates at any time during the term of this Agreement that is after March 31, 2020, DCI shall be obligated to effect such expansion but CRTX shall have no obligation to share the costs of expansion unless the Initial Term (as defined in
Section 11(a)) is extended by at least an additional five (5) years. 

  

	 	(ii)	Second Source of Manufacturing. CRTX shall have the right, and DCI hereby grants CRTX the right to establish a second source for manufacturing the Products to be
utilized only in the circumstances set out in paragraph (iii) below. CRTX shall bear all costs of establishing a second source of manufacture for the Products. DCI shall cooperate as necessary in facilitating the qualification of and transfer
of technology to such second source of manufacturing including providing a representative of such source with access, subject to the receipt of customary confidentiality undertakings, to the Back Up Manufacturing Data. DCI shall have authority to
oversee the transfer of technology to such second source of manufacturing, including but not limited to the facility and equipment qualifications, process validation, manufacture of stability batches, and submission of associated regulatory
documentation. 

  

	 	(iii)	Grant of Manufacturing Rights. Notwithstanding the foregoing provisions, DCI hereby grants to CRTX the right to manufacture the Products in quantities sufficient
to meet the forecast demand in the CF Market, but that right shall be exercisable only in the event that (A) DCI fails to meet forecast demand for six (6) consecutive months, or (B) there is a Force Majeure event (as defined in
Section 19) that prevents DCI from supplying the Products. 

  
 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

  
 Page 8 of 74

 Corrected and Restated 
  

	 	(iv)	Back Up Manufacturing Data. DCI shall submit all dossiers and materials incorporating the sources of all raw materials and all manufacturing specifications
procedures, know-how and master batch records (collectively, the “Back Up Manufacturing Data”), to be held in escrow by a third party, pursuant to the terms of a Back Up Manufacturing Data Escrow Agreement substantially in the form
attached as Exhibit G. DCI shall be responsible for updating the Back Up Manufacturing Data as appropriate to ensure they remain current. CRTX shall be entitled to receive all the materials held in escrow under the Back Up Manufacturing Data Escrow
Agreement at such time as CRTX’s right to manufacture under Section 5(b)(iii) becomes exercisable. 

  

	 	(v)	Ordering. DCI shall be solely responsible for fulfilling all CRTX Orders and ensuring that the Products are timely shipped in fulfillment of CRTX Orders. DCI
shall ensure that sufficient inventories of the Products are maintained at the entrance point in the supply chain, that upon entry into the supply chain, Products have at least twelve (12) months of remaining shelf life, and that the Products
are readily available for delivery to customers at all times. DCI agrees to accept and fulfill all CRTX Orders for Products up to one hundred ten percent (110%) of the most recently forecasted demand. 

 

	 	(vi)	Suspension of Performance. Notwithstanding anything contained in this Agreement, CRTX shall additionally have the right to notify the Steering Committee of its
intention to suspend its performance of its promotional and detailing activities : (A) in the event that DCI fails or is unable to timely supply Products to satisfy demand as provided in section 5(b)(iii); (B) in the event that DCI fails
or is unable to maintain the continued effectiveness of the regulatory approval for the Products (the continuation of which shall be deemed not to have been maintained if the FDA suspends the manufacturing, use, marketing, sale, or promotion of the
Products), or (C) in the event of a large-scale recall, large-scale market withdrawal, or similar corrective action with respect to the Products. If thirty (30) days elapse and the Steering Committee is unable to agree upon a solution that
corrects the situation referred to above, the matter shall be treated as a dispute, and until such dispute is resolved CRTX shall be released from its obligation to perform promotional and detailing activities, and such obligation shall be
reinstated only if and when (1) DCI has cured the issue to CRTX’s reasonable satisfaction and (2) DCI has reasonably satisfied CRTX that DCI can continue to satisfy the requirements of this Agreement on a going-forward basis, at which point CRTX shall use reasonable efforts to resume its promotional and detailing activities under this Agreement. The release of CRTX from its obligations pursuant to this paragraph
shall be in addition to all other rights and remedies available to CRTX under this Agreement, at law or in equity or otherwise, with respect to the event(s) triggering such release. 

  
 Page 9 of 74

 Corrected and Restated 
  

	 	(c)	Support for DCI CF Sales Force. DCI shall continue to pay commissions to its sales force from the Effective Date through June 30, 2013, as may be necessary
and appropriate to ensure that the CF Sales Force can assume its responsibilities without any interruption in sales or customer relations. In addition to the foregoing, DCI agrees that CRTX shall be free to adopt (and fund) a bonus plan or other
incentive package for the transitioning DCI representatives that will appropriately align their interests with those of the CF Sales Force. 

  

	 	(d)	Regulatory Reporting. DCI shall be responsible for handling all regulatory inquiries whether or not related to the CF Market. DCI shall be responsible for all
regulatory reporting requirements and performing all other functions related to regulatory which CRTX is not specifically responsible for under this Agreement. DCI shall be responsible for the timely reporting and investigation of all product
quality complaints. DCI shall be responsible for reporting all adverse event information (Expedited and Periodic Adverse Drug Experience Reports (PADERS)) to appropriate regulatory authorities in accordance with applicable legal
requirements. DCI shall also be responsible for adverse event related activities including but not limited to reviewing scientific literature, signal detection, record retention, maintaining data privacy, and preparing and delivering ad-hoc
reports requested by health authorities and audits. 

  

	 	(e)	Relations with Wholesalers. DCI shall be primarily responsible for negotiating agreements with wholesalers covering sales of the Products that are not purchased
primarily for distribution in the CF Market; to the extent that such existing contracts, if any, are assignable and relate to Products that are purchased by Target Customers, DCI shall assign them to CRTX. 

 

	 	(f)	Regulatory Compliance. Except as set forth in Section 3(d), and except as may be required under the terms of the Quality Agreement, DCI shall be responsible
for all communication with any governmental agencies and for satisfying all regulatory requirements relating to the promotion and sale of the Products in the Territory, including any post marketing clinical or reporting requirements.

  

	 	(g)	 Prosecution and Maintenance of Intellectual Property. DCI will maintain at its own cost all issued US patents covering the composition or use of
the Products including payment of all maintenance fees. DCI will vigorously prosecute any pending patents in the Territory relating to the Products, and, to the extent such pending patents include claims that may cover the use of the Products to
treat CF, will provide CRTX with an opportunity to review and comment on any patent office submission relating to such pending patents. In the event that DCI does not intend to prosecute, or does not timely prosecute, any such pending patent, then
(i) CRTX shall have the right to prosecute it at CRTX’s own discretion and at CRTX’s own expense, and (ii) DCI shall take such actions as are necessary to

  
 Page 10 of 74

 Corrected and Restated 
  

	 	
enable CRTX to so prosecute such pending patent application and (iii) DCI hereby grants to CRTX a perpetual exclusive Revenue Split free license to practice any resulting patent but such
prosecution shall not obligate DCI to relinquish any other rights of intellectual property and ownership of patents to CRTX. 

  

	 	(h)	Defense of Intellectual Property. DCI will vigorously assert and defend the patents in the Territory covering the Products and their use, and will take all
reasonable measures, taking into account the cost and potential commercial benefit of such actions at its sole discretion, to seek to enjoin the entry into the market of any generic product that might infringe such patents. In the event that DCI
does not intend to assert or defend any such patent, DCI shall grant to CRTX the right to assert and/or defend it at CRTX’s own discretion and at CRTX’s own expense but such defense shall not obligate DCI to relinquish any such rights of
intellectual property and ownership of patents to CRTX. 

  

	 	(i)	Damages. In the event that as a result of assertion of intellectual property rights there is a final, non-appealable award of costs and or damages in favor of
either or both of the Parties, all of such awards shall be apportioned as follows: (A) first, to reimburse the Party asserting the intellectual property rights for all costs incurred by that Party, including actual attorneys’ fees, in
asserting such rights; (B) second, to reimburse the other Party for all costs incurred supporting the efforts of the Party asserting the intellectual property rights, including actual attorney’s fees, with (C) the remainder, if any,
to be apportioned between the Parties whereby CRTX receives the CF Percentage of such remainder, and DCI receives a percentage of such remainder equal to one hundred percent (100%) minus the CF Percentage. 

 

	 	(j)	Reports. Within 45 (forty-five) days of the end of each calendar quarter, DCI shall submit to the Steering Committee a report setting out all the items listed on
Exhibit E and all information in DCI’s possession that bears on the calculation of Net Sales in the CF Market (the “DCI Quarterly Report”). 

 

	6.	Ordering; Logistics; Invoicing; Collection. 

  

	 	(a)	CRTX Orders. CRTX shall have the sole right to solicit orders from Target Customers in the Territory in the CF Market as described in Section 1(a), and
shall arrange for a copy of any such order (a “CRTX Order”) to be simultaneously conveyed to the DCI order processing. DCI shall treat any such order as an order placed by CRTX for drop shipment to the Target Customer’s address
referenced on the order. CRTX shall be responsible for shipping costs. 

  

	 	(b)	Invoice for Products from DCI to CRTX. Upon receipt of a CRTX Order for Products, DCI shall issue an invoice, upon shipment of the Product covered by such CRTX
Order, to CRTX in an amount calculated according to the procedure set out on Exhibit H (“Estimated Revenue Split”). Such invoice shall be payable net thirty (30) days. 

  
 Page 11 of 74

 Corrected and Restated 
  

	 	(c)	Unanticipated Costs. In the event that DCI incurs direct manufacturing costs, or costs resulting from a change in regulation, which are not reasonably
foreseeable, which are not caused by the negligence, wrongdoing or breach of this Agreement by DCI, [***], then upon DCI’s request the Steering Committee shall determine whether a change in the Estimated Revenue Split and/or the manner of
paying the same may be appropriate in order to ensure that such costs are equitably apportioned between the Parties. 

  

	 	(d)	CRTX Order Fulfillment. Subject to Section 5(b)(v), DCI shall be solely responsible for fulfilling all CRTX Orders. DCI shall notify CRTX of all shipments
of Products covered by CRTX Orders, providing applicable shipping documentation upon request. 

  

	 	(e)	Invoicing and Collection for CRTX Orders. CRTX shall be responsible for directly invoicing Target Customers for Products covered by CRTX Orders. CRTX shall also
be responsible for collecting all payments due under invoices that it issues for the Products. 

 7. Financial Definitions

 Wherever used in this Agreement, the following terms shall have the following meanings: 

 

	 	(a)	“Net Sales” means the gross amount recorded by CRTX or DCI (respectively) for bona fide sales of Products to an unrelated third party, less the
following amounts actually incurred or accrued in accordance with U.S. generally accepted accounting principles applied in a consistent manner: 

  

	 	(i)	Credits or allowances granted for spoilage or damage related to the Products, returns, recalls or rejections of the Products, and price adjustments;

  

	 	(ii)	Normal and customary trade, quantity, and cash discounts actually allowed; 

 

	 	(iii)	Ordinary and necessary freight out, postage, shipping, insurance and other transportation charges to the extent included in the invoice price to a third party;

  
 [***]
Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

  
 Page 12 of 74

 Corrected and Restated 
  

	 	(iv)	Legally allowed chargebacks, rebates and fees or similar payments actually granted to customers, including, without limitation, pharmacy benefit management companies,
health maintenance organizations, managed care organizations, federal, state, local and other governments, their agencies and purchasers and reimbursers; 

  

	 	(v)	Sales, use or value-added taxes imposed on sale of the Products; 

  

	 	(vi)	Launch discounts, stocking fees and other discounts extended to wholesalers, distributors, chain drug stores and other third party organizations who distribute the
Products; 

  

	 	(vii)	Credit card processing charges and fees; and 

  

	 	(viii)	any amounts actually written off or specifically identified as uncollectible in accordance with GAAP; 

solely to the extent the above deductions are taken in accordance with GAAP applicable to the particular selling entity. 

Use of Products for promotional, sampling or compassionate use purposes or for use in clinical trials (but excluding post-approval
clinical trials for which compensation is received by the selling entity) shall not be considered in determining Net Sales. 

Co-pay assistance amounts paid shall not be deducted from gross receipts in calculating Net Sales. 

In the case of any sale of Products between a Party and its affiliates or sublicensees for resale, Net Sales shall be calculated as above
only on the first arm’s length sale thereafter to an unrelated third party. 
 A Net Sale shall be deemed to have been made
upon the date such sale is so recorded in accordance with GAAP. 
  

	 	(b)	 “The CF Market” shall mean all prescriptions for the Products in the Territory identified to a diagnosis code that is related to CF
plus a percentage of any prescriptions for the Products in the Territory that are not identified to a particular diagnosis code. The amount of such unidentified prescriptions that will be considered to be part of the CF Market shall be determined by
multiplying the amount of such unidentified prescriptions by a fraction, the numerator of which is (X) all prescriptions written for the Products that are identified to a diagnosis code that is related to CF and the denominator of which is
(Y) all prescriptions written for the Products. Expressed as a percentage, such fraction is referred to as the “CF Percentage.” The data on which these calculations are based shall be

  
 Page 13 of 74

 Corrected and Restated 
  

	 	
derived from (i) prescription level data provided to CRTX by specialty pharmacies within CRTX’s promotion network, and (ii) prescription level data provided to and reported by IMS
or SHA and reported to CRTX. 

 Exhibit I sets forth examples of the use of these definitions to calculate Net
Sales and Exhibit J sets forth examples of the use of these definitions in the calculation of the CF Market. 
 8. Financial Terms - Lump Sum
Payments 
  

	 	(a)	Escrow Payment at Execution. Subject to the fulfillment of the condition precedent set forth in Section 29 below, CRTX shall, within seven (7) days
after the execution and delivery of this Agreement by both Parties, pay the amount of Ten Million U.S. Dollars ($10,000,000) (The “Escrow Payment”) into an escrow account that is subject to the terms and conditions of the Escrow Agreement
attached as Exhibit Q to this Agreement, which amount shall be released from escrow only in the circumstances and for the purposes and in the manner described in Exhibit M. 

 

	 	(b)	First Milestone. Within sixty (60) days after the end of the calendar quarter in which the cumulative total of Net Sales in the CF Market after the
Effective Date reaches Five Million U.S. Dollars ($5,000,000), CRTX shall pay to DCI the amount of Five Million U.S. Dollars ($5,000,000) (The “First Milestone”). 

 

	 	(c)	Second Milestone. Within sixty (60) days after the end of the first calendar year in which the total of Net Sales in the CF Market in such calendar year
exceeds Ten Million U.S. Dollars ($10,000,000), CRTX shall pay to DCI the amount of Two Million and Five Hundred Thousand U.S. Dollars ($2,500,000) (The “Second Milestone”). 

 

	 	(d)	Third Milestone. Within sixty (60) days after the end of the first calendar year in which the total of Net Sales in the CF Market in such calendar year
exceeds Fourteen Million U.S. Dollars ($14,000,000), CRTX shall pay to DCI the amount of One Million and Five Hundred Thousand U.S. Dollars ($1,500,000) (The “Third Milestone”). 

 

	 	(e)	Fourth Milestone. Within sixty (60) days after the end of the first calendar year in which the total of Net Sales in the CF Market in such calendar year
exceeds Eighteen Million U.S. Dollars ($18,000,000), CRTX shall pay to DCIthe amount of Five Million and Five Hundred Thousand U.S. Dollars ($5,500,000) (The “Fourth Milestone”). 

 

	 	(f)	Fifth Milestone. Within sixty (60) days after the end of the first calendar year in which the total of Net Sales in the CF Market in such calendar year
exceeds Thirty-Three Million U.S. Dollars ($33,000,000), CRTX shall pay to DCI the amount of Five Million and Five Hundred Thousand U.S. Dollars ($5,500,000) (The “Fifth Milestone”). 

 

	 	(g)	Multiple Milestones. If more than one (1) milestone is passed in a calendar year, the milestones due in respect of all such milestones shall be due within
sixty (60) days after the end of such calendar year. 

  
 Page 14 of 74

 Corrected and Restated 
  

 9. Financial Terms - Revenue Split and Copromotion Revenue Payments 

CRTX shall make Revenue Split payments to DCI and DCI shall make Copromotion Revenue payments to CRTX on a quarterly basis, as follows:

  

	 	(a)	Revenue Split Calculation. The CRTX Quarterly Report delivered pursuant to Section 4(e) shall include (i) a calculation of Revenue Split payable,
(ii) a summary of the data in CRTX’s possession necessary to calculate Net Sales in the CF Market for such calendar quarter and to enable DCI to comply with its government reporting requirements under those programs referenced in
Section 10(b) (“Governmental Programs”), and (iii) all Estimated Revenue Split amounts paid by CRTX , in the quarter covered by the CRTX Quarterly Report. Estimated Revenue Split amounts paid by CRTX for Products purchased at
Estimated Revenue Split amounts shall be offset against the Revenue Split payable by CRTX to DCI in respect of such quarter. Exhibit O provides an excel sheet and an example of this calculation. 

 

	 	(b)	Copromotion Revenue Calculation. The DCI Quarterly Report delivered pursuant to Section 5(j) shall include (i) a calculation of Copromotion Revenue
payable, and (ii) a summary of the data in DCI’s possession necessary to calculate Net Sales in the CF Market for such calendar quarter. 

  

	 	(c)	Review and Reconciliation. Each Party shall have a maximum of thirty (30) days from the date of receipt of the data supplied by the other Party pursuant to
Sections 9(a) and 9(b), respectively, to review such data and to dispute the contents thereof, and to determine what adjustments to it may be appropriate. Such adjustments shall include, but not be necessarily limited to, (i) taking into
account amounts collected by CRTX in respect of sales that are not in the CF Market, (ii) making arrangements for CRTX to reimburse DCI an amount that is a portion of any rebates (except rebates relating to sales of Product made before the
Effective Date of this Agreement) actually paid by DCI in any quarter pursuant to any Governmental Programs that is equal to the CF Percentage for such quarter, and (iii) adjusting such amount to take account of which Party negotiated the Best
Price or similar standard used in calculating such rebates, and the extent to which such reference price differs from the lowest equivalent price negotiated by the other Party. 

  
 Page 15 of 74

 Corrected and Restated 
  

	 	(d)	Payment. At the completion of such maximum thirty (30) day period, (i) CRTX shall make a Revenue Split payment to DCI in the amount of [***] of the
undisputed portion of the Net Sales in the CF Market that is attributable to CRTX Orders for such quarter, as offset by Estimated Revenue Split amounts paid by CRTX, and (ii) DCI shall make a Copromotion Revenue payment to CRTX in the amount of
[***] of the undisputed portion of the Net Sales in the CF Market that is attributable to DCI’s sales of the Products for such quarter. 

  

	 	(e)	Disputes. In the event either Party disputes any portion of the calculated Revenue Split or Copromotion Revenue for a given quarter, the disputing Party shall
have the right to particular data underlying such dispute. The audited Party shall arrange a mutually convenient time for such audit, which shall be within normal business hours, shall be at the audited Party’s place of business, shall not
exceed three (3) days in duration and shall be entirely at the auditing Party’s expense. In the event that the audit does not conclusively resolve the dispute, it shall be settled pursuant to the dispute resolution and arbitration
procedures set forth in Section 17. 

  

	 	(f)	Trailing Consideration. In the event that this Agreement is terminated for any reason defined in this Agreement prior to the expiration of its Initial Term, DCI
shall continue to calculate Net Sales in the CF Market for a further eight (8) calendar quarters or, if this Agreement would otherwise have expired before the end of the eighth such quarter, up to the original expiration date, and shall pay
CRTX [***] of such amount within ninety (90) days of the end of each calendar quarter, subject to the dispute resolution and arbitration procedures set forth in Section 17, provided, however, that quarterly payments not to exceed the
average of the last two (2) quarters prior to termination, and aggregate payments shall not exceed the Revenue Split paid by CRTX in the last eight (8) quarters prior to termination. 

 

	 	(g)	Maintenance of Books and Records. Each Party shall maintain all books and records necessary to calculate the Net Sales, and Net Sales in the CF Market for seven
(7) years after the end of the calendar year to which such books and records pertain. 

 10. Rebates, Returns and Recalls.
 
  

	 	(a)	NDC Numbers. All sales of Products shall be made under DCI’s existing National Drug Code (“NDC”) numbers. 

 
 [***] Confidential portions of the
exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

  
 Page 16 of 74

 Corrected and Restated 
  

	 	(b)	Government Rebates. DCI shall have all of the responsibility for entering into contracts to pay, and paying all rebates that are payable pursuant to any
government rebate programs with respect to the Products and for filing all necessary documentation relating to the reporting of Average Manufacturer Price (as defined in the Social Security Act, 42 U.S.C. §1396r-8(k)) and Best Price (as defined
in the Social Security Act, 42 U.S.C. § 1396r-8(c)(1)(C)), or other data or information regarding sales, timing and pricing, for the Products as required by the applicable Governmental Program. Each Party will in a timely manner provide to the
other Party any information required to comply with these reporting requirements. “Governmental Programs” shall include, but not be limited to, Medicaid, Medicare Part D, Public Health Section 340B, TriCare and the Department of
Defense/Department of Veterans Affairs. 

  

	 	(c)	Commercial Rebates. Each Party shall have absolute discretion to negotiate the terms and conditions of all customer agreements with non-governmental payors, that such Party desires to enter into and that provide for a rebate or chargeback or similar discount arrangement. Each Party shall have sole responsibility for paying all rebates that are
payable pursuant to any such customer agreements that such Party concludes with a customer; provided that in no event shall the foregoing require CRTX to make payment of any rebate covered by Section 10(b), all of which shall be paid solely by
DCI. 

  

	 	(d)	Returns to CRTX. All invoices for CRTX Orders shall include a provision requiring returns of Products to be made through a returns processor nominated by CRTX
and approved by the Steering Committee. CRTX shall be financially responsible for all returns of Products sold pursuant to CRTX Orders and returned through the nominated returns processor. 

 

	 	(e)	Other Returns. DCI shall be financially responsible for all other returns of Products made by any customer at any time. If any Product other than a Product sold
pursuant to a CRTX Order is returned to CRTX, CRTX will promptly transfer such returned Product to DCI for processing. To the extent that returned Products are returned to DCI by a customer of CRTX, DCI shall promptly process such return in
accordance with DCI’s Return Goods Policy as referenced in Exhibit N and so advise CRTX and CRTX shall take such steps as may be necessary to ensure that such customer is properly credited and that documentation sufficient to support the
determination of the appropriate customer credit and its issuance is provided to DCI. 

  

	 	(f)	Recalls. DCI shall inform and seek and consider the input of CRTX with respect to decisions and actions relating to the recall or proposed recall of any of the
Products but shall be ultimately responsible for all such decisions. All third party or out of pocket costs of recall, including costs related to the return of Product in a recall, will be borne by DCI. CRTX will assist in any recall activities. DCI
shall replace Products returned as a result of a recall at its own cost and expense. 

  
 Page 17 of 74

 Corrected and Restated 
  

 11. Term of Agreement 

 

	 	(a)	Initial Term. This Agreement shall become effective on the Effective Date and unless otherwise terminated or renewed pursuant to its terms, shall have an initial
term of ten (10) years (the “Initial Term”). 

  

	 	(b)	Extension Term. After the Initial Term, this Agreement shall renew automatically for successive additional terms of two (2) years each (each an
“Extension Term”) unless either Party provides written notice to the other that it does not wish to renew the agreement, and such notice is received at least six (6) months prior to the expiration of the Initial Term or the then
current Extension Term, as applicable. 

 12. Termination. 

 

	 	(a)	Automatic Termination. This Agreement shall terminate upon written notice of the Party not suffering the event to the other if the other Party enters proceedings
in bankruptcy, voluntarily or involuntarily, or becomes unable, in the ordinary course of business, to pay its obligations in a timely manner. 

  

	 	(b)	Termination by DCI. DCI may terminate this Agreement: 

  

	 	(i)	upon ninety (90) days written notice to CRTX if CRTX is in breach of any material obligation under this Agreement, and such breach is not cured within such ninety
(90) day period; or 

  

	 	(ii)	upon thirty (30) days written notice if (A) Net Sales in the four (4) calendar quarters preceding July 1, 2016 are less than Seven Million U.S.
Dollars ($7,000,000); and (B) if upon receipt of such notice, CRTX does not, within fifteen (15) days, make a pre-payment to DCI of Revenue Split in an amount equal to the difference between the amount of the Revenue Split payments DCI
would have received had Net Sales been Ten Million U.S. Dollars ($10,000,000) and the amount of Revenue Split payments DCI had actually received during such four calendar quarters, and (C) during such period, there has been no interruption in
the supply of Products; or 

  

	 	(iii)	upon thirty (30) days written notice if (A) Net Sales in the four (4) calendar quarters preceding July 1, 2018 are less than Eighteen Million U.S.
Dollars ($18,000,000) and (B) upon receipt of notice CRTX does not, within fifteen (15) days, make pre-payment to DCI of (if not previously paid) the Third Milestone and the Fourth Milestone; and (C) during such period there has been
no interruption in the supply of Products. 

 provided, however, that as a condition to its exercise of its rights
under paragraphs (ii) or (iii) above, DCI shall pay to CRTX an amount equal to all of the Milestone payments, if any, paid by CRTX to DCI through the date of termination pursuant to Sections 8(b) through 8(f) above (but not
Section 8(a)). 

  
 Page 18 of 74

 Corrected and Restated 
  

	 	(c)	Termination by CRTX. CRTX may terminate this Agreement upon ninety (90) days written notice to DCI if: 

 

	 	(i)	DCI is in breach of any material obligation under this Agreement, and such breach is not cured within such ninety (90) day period; or 

 

	 	(ii)	a generic or branded generic version of any of the Products is approved for sale in the Territory; or 

 

	 	(iii)	DCI is unable to manufacture the Products or supply Products from a second source, sufficient to meet demand, for a period exceeding one hundred eighty (180) days,
and CRTX chooses not to exercise any of its rights to manufacture under Section 5(b) (iii); or 

  

	 	(iv)	DCI’s intellectual property is abandoned or is determined to be invalid, or the sale of the Products is suspended because an injunction is granted to a party who
alleges that the Products infringe such party’s intellectual property; or 

  

	 	(v)	DCI is enjoined by any governmental authority or regulatory agency from offering the Products for sale, including as a result of DCI’s failure to uphold its post-marketing commitments; 

  

	 	(vi)	At the first opportunity, but in any event within thirty (30) days after the completion of the GMP Audit and CRTX’s receipt of the GMP Audit Report, CRTX
determines and so notifies DCI that, in CRTX’s absolute discretion, its observations during the GMP Audit and/or findings in the GMP Audit Report make termination in the best interests of CRTX (an “Early Termination”);

  

	 	(vii)	If DCI informs CRTX that SPL will not or cannot take, or DCI does not intend to support SPL in taking, the corrective actions and address the deficiencies, if any,
referenced in the GMP Audit Report (“DCI Audit Refusal Notice”), CRTX, in its absolute discretion, may terminate this Agreement (“DCI Audit Refusal Termination”); provided, however, such DCI Audit Refusal Notice must be provided
to CRTX within thirty (30) days after receipt by CRTX of the GMP Audit Report. If DCI does not provide such DCI Audit Refusal Notice within such time period, it will be deemed to be that SPL has agreed to remedy, and DCI has agreed to
technically support SPL in remedying, all of the deficiencies noticed in the GMP Audit Report, and SPL has agreed to take, and DCI has agreed to technically support SPL in taking all of the corrective actions set forth in the GMP Audit Report; or

  

	 	(viii)	At the first opportunity, but in any event within thirty (30) days after CRTX acknowledgement of receipt by CRTX of SPL’s plan to address the corrective
actions and/or deficiencies, if any, referenced in the GMP Audit Report to be provided by DCI pursuant to 13(l), CRTX has determined, in its reasonable discretion, that the corrective actions and/or deficiencies, if any, referenced in such plan
cannot reasonably be completed or remedied by SPL or DCI within a reasonable time frame (an “Audit Termination”). 

  
 Page 19 of 74

 Corrected and Restated 
  

	 	(d)	Termination by either Party. A Party may terminate this Agreement upon as much notice as practicable in the event that a Force Majeure Event affecting the other
Party has persisted for more than one hundred eighty (180) days notwithstanding the good faith efforts of the Parties to rearrange their relationship in light of such event on an expedited basis. 

 

	 	(e)	Consequences of Termination. Upon expiration or termination of this Agreement for any reason, 

 

	 	(i)	all outstanding amounts payable by one Party to the other shall be calculated and agreed and the owing company shall pay the owed company in full within ninety
(90) days; 

  

	 	(ii)	each Party will discontinue any and all use of the other’s trademarks; 

 

	 	(iii)	CRTX will return and DCI will repurchase any unused samples, with payment for such samples being due within ninety (90) days; 

 

	 	(iv)	each Party will return to the other or destroy any confidential information of the other acquired during the term of this Agreement; 

 

	 	(v)	if there is an Early Termination or a DCI Audit Refusal Termination or an Audit Termination, all of the funds at such time remaining in the escrow established pursuant
to clause 8(a) shall be released in the manner provided for in Exhibit M; and 

  

	 	(vi)	Sections 1(e), 4(e) (to the extent relevant to activities occurring at expiration or termination of this Agreement), 5(d), 5(j) (to the extent relevant to activities
occurring at expiration or termination of this Agreement), 6(e) (to the extent relevant to activities occurring at expiration or termination of this Agreement), 7, 8 (to the extent the event giving rise to a payment thereunder occurs prior to the
effective date of expiration or termination, but subject to the requirement in Section 9, 10, 12(e) and 15 through 28 shall survive an expiration or termination of this Agreement in accordance with their respective terms).

  
 Page 20 of 74

 Corrected and Restated 
  

 13. DCI Covenants, Representations and Affirmations. 

 

	 	(a)	Authorization; No Conflict. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (i) are within the
corporate power of DCI and have been duly authorized by all necessary proceedings of DCI, and (ii) do not or will not: (A) conflict with or result in a breach of any provision of DCI’s organizational documents, (B) result in a
material breach of any material agreement to which DCI is a party, (C) result in a violation of any governmental order to which DCI is subject, (D) require DCI to obtain any material approval or consent from any governmental authority,
parent organization or third party, or (E) violate any legal requirement applicable to DCI in any material respect. 

  

	 	(b)	Financial Condition. DCI affirms that the information that it has provided to CRTX as to its financial condition is, and will at all times remain, true, complete
and correct in all material respects, and agrees to provide CRTX with such access to its books and records as CRTX may reasonably request in order to verify the continuing accuracy of such information. 

 

	 	(c)	Due Diligence. DCI agrees to grant to CRTX such access as it may reasonably request to conduct confirmatory due diligence, the satisfactory completion of which
shall be a condition precedent to the effectiveness of this Agreement. In addition, DCI covenants that it will: 

  

	 	(i)	for DCI’s fiscal year 2014, and every year thereafter that this Agreement is in force, DCI shall provide CRTX with financial statements audited by a certified
public accountant, licensed in Pennsylvania or New Jersey and in good standing. The audited financial statements shall consist of a balance sheet wherein the assets, liabilities and equity of the firm are disclosed, an income statement reporting the
revenues and expenses for the current fiscal year and explanatory notes, as well as the report of the auditor expressing the auditor’s conclusion based on the results of the audit. The audited financial statement shall be delivered to CRTX
within ninety (90) days of the close of DCI’s fiscal year; and 

  

	 	(ii)	regularly review its financial standing and immediately notify CRTX should its resources be such as to call into question its viability to function as a going concern
for at least the next twelve (12) months, having due regard to its GAAP assets and liabilities as well as known or potential liabilities that may arise. Following such notice, the Parties shall enter into good faith negotiations for the purpose
of restructuring this Agreement or identifying other solutions in order to avert the potential insolvency. 

  

	 	(d)	 Title to Assets and Products. DCI affirms that, except as referenced in Section 29 of this Agreement, it (i) owns in its own right the
entire right, title and interest in all the assets necessary to operate the business of manufacture, distribution and sale of the Products in the manner in which such business is currently conducted,

  
 Page 21 of 74

 Corrected and Restated 
  

	 	
and in the Products, free and clear of any security interest, lien, encumbrance, pledge, assignability or transferability restriction, community property or other spousal partner interest or
other burden of any nature whatsoever, that would interfere with the exclusive license granted to CRTX pursuant to this Agreement, and (ii) is in its own right a party to all contractual agreements or arrangements that are necessary to operate
the business of manufacture, distribution and sale of the Products in the manner in which such business is currently conducted. 

  

	 	(e)	Regulatory Compliance. DCI covenants that it will timely fulfill all post-marketing requirements imposed by FDA in connection with the approval of the New Drug
Application for the Product. DCI affirms that it has not received any indication from the FDA or any other governmental authority or regulatory agency that the Products (including their packaging and labeling) do not comply with applicable
regulatory requirements. 

  

	 	(f)	No Defects. DCI affirms that the Products (including packaging and labeling) delivered to customers will be manufactured in accordance with cGMP, meet all
applicable as well as the requirements of the Quality Agreement and are not misbranded or adulterated and that each Product is identifiable to a particular batch number. 

 

	 	(g)	Shelf Life. DCI affirms that the Products when delivered to specialty pharmacies or other customers in the CF Market will have at least twelve (12) months
of shelf life. 

  

	 	(h)	Developments. DCI affirms that it has disclosed to CRTX all of its plans to develop enhanced or successor presentations of the Products and will continue to
promptly make such disclosures at all times during the term of this Agreement. 

  

	 	(i)	Intellectual Property. DCI affirms that to the best of its knowledge the Products do not infringe the intellectual property rights of any third party, and that
to its knowledge no claims exist alleging such infringement. DCI further affirms that to its knowledge no claims exist alleging the invalidity of the patents covering the Products. 

 

	 	(j)	Government Programs. DCI affirms that all information provided to any governmental authority in connection with sales of the Products or rebates due with respect
to such sales has been and will be complete and accurate in all material respects and that CRTX may rely upon such information in fulfilling its regulatory reporting obligations. 

 

	 	(k)	No Conflicts. DCI affirms that it is not a party to any agreement that would prevent it from fulfilling its obligations under this Agreement.

  
 Page 22 of 74

 Corrected and Restated 
  

	 	(l)	Supply Agreement. DCI covenants and affirms that: 

  

	 	(i)	it will audit the compliance with Good Manufacturing Practices of its raw material supplier Scientific Protein Laboratories LLC (“SPL”) on or about
June 4, 2013 and will (A) provide CRTX, or representatives of CRTX, with the opportunity to review the audit plan and to attend, observe and participate in such audit and (B) will furnish CRTX a true and complete copy of the resulting
report (the “GMP Audit Report”) as soon as the same is available, and (C) will furnish CRTX a true and complete copy of SPL’s plan to address the corrective actions and/or deficiencies, if any, referenced in the GMP Audit Report
as soon as the same is available and obtain written acknowledgement by CRTX of receipt of the same. 

  

	 	(ii)	it will assist and support SPL in taking any corrective actions that such audit and the resulting report may recommend; 

 

	 	(iii)	it will procure, and deposit with the Back-Up Manufacturing Data, within one hundred eighty (180) days of the Effective Date, the consent of SPL to the assignment
to CRTX of DCI’s rights and obligations under the Supply Agreement dated January 15, 2013 between DCI and SPL, which consent shall be (A) effective as of release of the consent document to CRTX from the escrow (and CRTX can date such
consent the date of release of the consent from escrow) and (B) in form and substance reasonably acceptable to CRTX. 

 14.
CRTX Covenants, Representations and Affirmations. 
  

	 	(a)	Authorization; No Conflict. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (i) are within the
corporate power of CRTX and have been duly authorized by all necessary proceedings of CRTX, and (ii) do not or will not: (A) conflict with or result in a breach of any provision of CRTX’s organizational documents, (B) result in a
material breach of any material agreement to which CRTX is a party, (C) result in a violation of any governmental order to which CRTX is subject, (D) require CRTX to obtain any material approval or consent from any governmental authority,
parent organization or third party, or (E) violate any legal requirement applicable to CRTX in any material respect. 

  

	 	(b)	[intentionally omitted] 

  

	 	(c)	No Conflicts. CRTX affirms that it is not a party to any agreement that would prevent it from fulfilling its obligations under this Agreement.

  

	 	(d)	 Due Diligence. CRTX agrees to grant to DCI such access as it may reasonably request to conduct confirmatory due diligence, the satisfactory
completion of which shall be a condition precedent to the effectiveness of this Agreement. In addition, for any fiscal year in which CRTX is not required to make public disclosures on SEC Forms 10-Q and 10-K, for so long as this Agreement is in
force, CRTX shall provide DCI with financial statements audited by a certified 

  
 Page 23 of 74

 Corrected and Restated 
  

	 	
public accountant, licensed in North Carolina and in good standing. The audited financial statements shall consist of a balance sheet wherein the assets, liabilities and equity of the firm are
disclosed, an income statement reporting the revenues and expenses for the current fiscal year and explanatory notes, as well as the report of the auditor expressing the auditor’s conclusion based on the results of the audit. The audited
financial statement shall be delivered to DCI within ninety (90) days of the close of CRTX’s fiscal year. 

 15.
Relationship of the Parties. In fulfilling its obligations under this Agreement, CRTX is acting as an independent contractor. Except as contemplated under this Agreement, it does not have the right to, and will not at any time hereafter
without DCI’s prior written consent, transact any business in the name of DCI or obligate it in any manner, character or description. Absent its prior written consent, DCI shall not, under any circumstances, be liable for any agreement,
contract, representation or warranty which CRTX has made or may enter into or make. CRTX shall indemnify and hold DCI harmless from the consequences of representations or warranties made by CRTX except as expressly authorized by DCI in writing. This
Agreement does not establish or create a partnership or joint venture among the Parties. 
 16. Compliance with Laws. Each Party shall in
all material respects conform its practices and procedures relating to the marketing, detailing and promotion of the Products in the Territory to all applicable laws, regulations and guidelines, including, but not limited to, the Food, Drug and
Cosmetic Act, the Food and Drug Administration Amendments Act of 2007, the Prescription Drug Marketing Act, the Anti-Kickback Statute (42 U.S.C. 1320a-7b(b)), the Generic Drug Enforcement Act of 1992 and the American Medical Association
(“AMA”) Guidelines on Gifts to Physicians from Industry (the “AMA Guidelines”), as the same may be amended from time to time. Each of DCI and CRTX shall promptly notify the other Party of and provide such Party with a copy of any
material adverse correspondence or other reports with respect to the promotion of the Products that is received from the marketplace, or from the U.S. Department of Health and Human Services or its components (including the FDA and the Office of the
Inspector General), or from the AMA relating to such laws, regulations and guidelines. 
 17. Dispute Resolution. 

 

	 	(a)	Steering Committee. The Parties shall attempt in good faith to resolve any dispute arising out of or relating to this Agreement promptly by negotiation in the
forum of the Steering Committee. 

  

	 	(b)	Executives. Subject to Section 2(e), if the Steering Committee is unable to resolve any dispute, or if any dispute arises that is not related to the matters
specifically delegated to the Steering Committee under this Agreement, it shall be referred to the Chief Executives of the Parties who shall negotiate in good faith for a period of up to thirty (30) days to reach a reasonable solution.

  
 Page 24 of 74

 Corrected and Restated 
  

	 	(c)	Mediation. Any dispute that has not been resolved by the Chief Executives after thirty (30) days shall be referred to mediation before a mediator that is
mutually acceptable to the Parties, and such mediation shall be conducted as soon as practicable, but in no event after more than a further sixty (60) days. 

 

	 	(d)	Arbitration. Any claim of either Party that arises out of a dispute that has not been resolved through mediation shall be settled by arbitration in accordance
with the then current Center for Public Resources Rules for Non-Administered Arbitration of Business Disputes by three (3) independent and impartial arbitrators. Each Party shall appoint one (1) arbitrator, and the two (2) arbitrators
will select a third. The arbitration shall be governed by the United States Arbitration Act, 9 U.S.C. §1-16. The Parties agree that limited discovery shall be allowed in accordance with the Federal Rules of Civil Procedure, Rule 26(a)(1) -
(3) (as in effect on the date hereof), which disclosure shall be made within sixty (60) days of the initiation of arbitration. All issues regarding compliance with this mandatory disclosure shall be decided by the arbitrators pursuant to
the Federal Rules of Civil Procedure, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof. 

  

	 	(e)	Choice of Law. The arbitrators shall determine the dispute in accordance with this Agreement and the substantive rules of law (but not the rules of procedure) of
the State of New York. The place of arbitration shall be in the State of New York. 

  

	 	(f)	Injunctive Relief. Nothing in this Article 17 shall limit the Parties rights to seek injunctive relief under the Confidentiality Agreement.

  

	 	(g)	Step In Rights. Nothing in this Article 17 shall limit the right of either Party, after initiation of the dispute resolution procedures envisaged in this
Section 17, to step in and take any action on behalf of the other Party that is reasonably necessary to ensure the continued lawful sale of Products in the CF Market, and to the extent the Party so stepping in incurs out of pocket expenses in
taking such action on behalf of the other Party, it may offset such expenses against its financial obligations to the other Party under this Agreement until such time as any underlying dispute is finally resolved. 

18. Confidentiality; Public Announcements. 
  

	 	(a)	The Parties have previously executed a Confidentiality Agreement (the “Confidentiality Agreement”) and an amendment thereto, both of which appear as Exhibits
L and L-1, and are hereby incorporated by Reference in this Agreement and made a part hereof, provided, however, that, the uses of confidential information permitted under the Confidentiality Agreement shall include all uses that may be necessary or
desirable to enable CRTX to perform its obligations under this Agreement, and to the extent that any provisions of the Confidentiality Agreement conflict with any provisions of this Agreement, the provisions of this Agreement shall govern.

  
 Page 25 of 74

 Corrected and Restated 
  

	 	(b)	The Parties have agreed on an initial press release of the transaction contemplated by this Agreement which is attached hereto as Exhibit K (the “Initial Press
Release”). The Initial Press Release may be issued or used by each Party individually or by the Parties jointly on or after the Effective Date. Thereafter, each Party may disclose the information contained in such press release without need for
further approval by the other. 

  

	 	(c)	CRTX may make subsequent public disclosures from time to time after good faith consultation with DCI. DCI may make such public disclosures only with the approval of
CRTX, which approval will not be unreasonably withheld or delayed. When a Party (the “Requesting Party”) elects to make any such public disclosure, it will give the other Party (the “Cooperating Party”) at least five
(5) business days notice to review and comment on such statement, and in any event the Cooperating Party shall work diligently and reasonably to agree on the text of any proposed disclosure in an expeditious manner. 

19. Force Majeure. Neither Party shall be liable for failure or delay in fulfilling its obligations under this Agreement where such failure or
delay is due, in whole or in part, to intervention of any governmental authority or acts of regulatory agencies, fires, earthquakes, acts of God or causes beyond its reasonable control (each a “Force Majeure Event”). If a Force Majeure
Event occurs, the affected Party shall promptly notify the other Party, and the Parties shall attempt, in good faith, to rearrange their relationship, including by amicable termination, so as to minimize the ill effects of the event on each other.

 20. Notices. Wherever notice is required or permitted hereunder, it shall be by personal delivery, first class mail, overnight
delivery service, or sent by facsimile transmission, with electronic confirmation, properly directed to the Party at its address and contact information listed below, and shall be effective upon receipt in the case of personal delivery, overnight
delivery or facsimile, and five days after mailing in the case of first class mail. Said address and contact information may be changed from time to time by similar written notice. 

 

			
	If to CRTX:	 	If to DCI:
	Cornerstone Therapeutics Inc.	 	Digestive Care Inc.
	1255 Crescent Green Drive	 	1120 Win Drive
	Cary, NC 27518	 	Bethlehem, PA 18017
		
	Attention: General Counsel	 	Attention: Chief Executive Officer
	Phone: 9196786524	 	Phone: 610-882-5950
	Fax:     9196786599	 	Fax:     610-882-0349

  

  
 Page 26 of 74

 Corrected and Restated 
  

 21. Indemnification. 

 

	 	(a)	Indemnity. 

  

	 	(i)	Each Party (each, an “Indemnifying Party”) shall defend, at its own expense, indemnify, and hold harmless the other Party (the “Indemnified Party”)
and its Affiliates, and its and their respective directors, officers, employees, agents and other representatives (collectively, the “Indemnified Persons” of the Indemnified Party), from and against any and all damages, liabilities,
losses, costs, and expenses, including reasonable attorneys’ fees (“Losses”) arising out of any third party claim, suit or proceeding (“Claim”) brought against the Indemnified Party or its Indemnified Persons to the extent
such Claim arises out of or relates to (A) any breach or violation by the Indemnifying Party of, or failure to perform by the Indemnifying Party of, any representation, warranty, covenant, or other obligation in this Agreement, or the falsehood
of any affirmation of the Indemnifying Party, in each case unless waived in writing by the Indemnified Party; (B) the negligence or willful misconduct of the Indemnifying Party or any of its Indemnified Persons or its third party contractors
(including third party manufacturers or suppliers); (C) any violation of applicable laws by the Indemnifying Party or any of its Indemnified Persons or its third party contractors (including third party manufacturers or suppliers); or
(D) in the case of CRTX as the Indemnifying Party, any actions of the CF Sales Force, including any false or misleading representations to professionals, customers, or others regarding DCI or the Product; except to the extent, in each case,
((A), (B), (C) and (D)), any Losses for which the Indemnified Party has an obligation to indemnify the Indemnifying Party or its Indemnified Persons pursuant to this Section 21, as to which Losses each Party shall indemnify the other to
the extent of their respective liability for such Losses. 

  

	 	(ii)	In addition, DCI shall defend, at its own expense, indemnify, and hold harmless CRTX and its Indemnified Persons, from and against losses arising out of claims brought
against CRTX or its Indemnified Persons to the extent such claim arises out of or relates to (A) any claim made by any person that the manufacture, use, or sale of the Products infringes or misappropriates the patent, trademark, or other
intellectual property rights of such person, (B) any claim for products liability with respect to the Products, or (C) without limitation of clause (B), any claim based on death, personal injury, or property damage arising out of the
manufacture of the Products by or on behalf of DCI (including such manufacture or supply by third party manufacturers or suppliers to DCI’s specifications). 

 

	 	(iii)	 The Indemnified Party shall promptly notify the Indemnifying Party in writing of any claim and shall give the Indemnifying Party full information and
assistance in connection therewith. The Indemnifying Party’s 

  
 Page 27 of 74

 Corrected and Restated 
  

	 	
obligation to defend, indemnify, and hold harmless any Indemnified Person shall be reduced to the extent the Indemnified Party’s delay in providing notification pursuant to the previous
sentence results in prejudice to the Indemnifying Party. The Indemnifying Party shall have the sole right to control the defense and the sole right to settle or compromise the claim, except that the prior written consent of the Indemnified Party
shall be required in connection with any settlement or compromise that could (A) place any obligation on or require any action on the part of the Indemnified Party, (B) admit or imply any liability or wrongdoing on the part of the
Indemnified Party or (C) not provided a full release of claims in favor of the Indemnified Persons. Notwithstanding the foregoing, the Indemnified Party may participate in such defense through counsel of its choice, but the cost of such counsel
shall be borne solely by the Indemnified Party. 

  

	 	(b)	No Consequential Damages. Neither CRTX nor DCI shall be entitled to or liable for any indirect, special, contingent or consequential or punitive damages
including, without limitation, damages for loss of use, revenue, profit or product, operating costs, financing and interest costs and business interruption, however the same may be caused, including, without limitation, the fault, breach of
contract, tort (including the concurrent or sole and exclusive negligence), strict liability or otherwise of the other Party, even if such Party is advised of the possibility of such damages. 

 

	 	(c)	Insurance. DCI shall at all times maintain product liability insurance covering the Products and naming CRTX as an additional insured, in an amount not less than
Five Million U.S. Dollars ($5,000,000) aggregate and per occurrence. 

  

	 	(d)	Insurance. CRTX shall at all times maintain product liability insurance covering the Products and naming DCI as an additional insured, in an amount not less than
Five Million U.S. Dollars ($5,000,000) aggregate and per occurrence. 

 22. Governing Law. All questions concerning the
validity or meaning of this Agreement or relating to the rights and obligations of the Parties with respect to performance under this Agreement shall be construed and resolved under the laws of the State of New York. 

23. Severability. The intention of the Parties is to comply fully with all laws and public policies, and this Agreement shall be construed
consistently with all laws and public policies to the extent possible. If and to the extent that any arbitration panel determines that it is impossible to construe any provision of this Agreement consistently with any law or public policy and
consequently holds that provision to be invalid, such holding shall in no way affect the validity of the other provisions of this Agreement, which shall remain in full force and effect. 
 24. Failure or Omission. No failure or omission by either Party to insist upon or enforce any of the terms of this Agreement shall be deemed a waiver of such terms. 

  
 Page 28 of 74

 Corrected and Restated 
  

 25. Successors, Assignment, and Divestiture 

 

	 	(a)	Successors. Subject to Section 25(b), this Agreement is binding on the Parties and their successors in interest, including those that may succeed by
assignment, transfer or otherwise to the ownership of either of the Parties or of the assets necessary to the conduct of the business to which this Agreement relates. 

 

	 	(b)	Assignment. In the event that either Party contemplates the assignment of any of its rights or obligations under this Agreement, it shall so notify the other
Party in writing, and the other Party will have thirty (30) days in which either to consent in writing to such assignment or to provide written notice of its intention to terminate this Agreement effective ninety (90) days from the date of
such notice, provided, however, that no consent shall be required to an assignment to a party that is the majority owner of, is majority owned by, or under common majority ownership with, the assigning party, or is the acquirer or successor to all
of the business of the assigning party to which this Agreement relates. 

 26. Complete Agreement. This Agreement, along
with its exhibits, the Quality Agreement, and Escrow Agreement, constitute the entire agreement between the Parties, and cancels and supersedes any and all previous agreements between the Parties with respect to the subject matter hereof. All
modifications or amendments hereto must be in writing and signed by both Parties. No renewal, termination or cancellation of this Agreement, or modification or waiver of any of the provisions herein contained, or any future representation, promise
or condition in connection with the subject matter hereof, shall be binding unless it is made in writing, dated subsequently and signed on its behalf by an authorized officer or employee of each Party. A mere acknowledgement or acceptance of any
order containing different terms or otherwise inconsistent with the terms of this Agreement shall not be deemed an acceptance or approval of such inconsistent provisions. 
 27. Headings. The headings of the several sections hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several sections hereof. The
Parties acknowledge they have thoroughly reviewed this Agreement and mutually agreed upon its terms. 
 28. Public Disclosures. Neither
Party shall make any press release or other public disclosure describing the terms of this Agreement, or the relationship to which it refers, without first giving the other Party the opportunity to review and approve such disclosure. 

29. Family Partnership. DCI represents that those assets identified on Exhibit R are used in the operation of DCI’s business and are owned by
The Sipos Family Partnership (the “Partnership”). To acknowledge that the Partnership may therefore need to execute certain documents and take certain actions in order to effectuate the intentions of the parties as reflected in this
Agreement and the other agreements executed in connection with this Agreement, DCI will procure that, as a condition precedent to the effectiveness of this Agreement, the Partnership executes the Letter of Assurance attached to this Agreement as
Exhibit S. 

  
 Page 29 of 74

 Corrected and Restated 
  

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives: 
  

									
	Digestive Care, Inc.	 		 	Cornerstone Therapeutics Inc.
					
	By:	 	 /s/ Tibor Sipos
	 		 	By:	 	 /s/ Alastair McEwan

					
	Title:	 	 President
	 		 	Title:	 	 Chief Financial Officer

					
	Date:	 	 7-3-2013
	 		 	Date:	 	 2 July 2013

  
 Page 30 of 74

 Corrected and Restated 
  

 EXHIBIT A 
 PRODUCTS 
  

							
	CURRENTLY FDA APPROVED AND AVAILABLE:	 	
				
	Commercial	 		 		 	
				
	Pertzye 8000	 	NDC 59767-008-01	 	100 capsules/bottle	 	12 bottles/case
	Pertzye 8000	 	NDC 59767-008-02	 	250 capsules/bottle	 	6 Bottles/case
	Pertzye 16000	 	NDC 59767-016-01	 	100 capsules/bottle	 	12 bottles/case
	Pertzye 16000	 	NDC 59767-016-02	 	250 capsules/bottle	 	6 bottles/case
				
	Samples	 		 		 	
				
	Pertzye 8000	 	NDC 59767-008-99	 	100 capsules/bottle	 	12 bottles/case
	Pertzye 8000	 	NDC 59767-008-00	 	20 capsules/bottle	 	12 bottles/case
	Pertzye 16000	 	NDC 59767-016-99	 	100 capsules/bottle	 	12 bottles/case
	Pertzye 16000	 	NDC 59767-016-00	 	20 capsules/bottle	 	12 bottles/case
	
	FUTURE DEVELOPMENT:
				
	Commercial	 		 		 	
	Pertzye [***]	 	NDC 59767-[***]-XX	 	100 capsules/bottle	 	12 bottles/case
	Pertzye [***]	 	NDC 59767-XXX XX	 	100 capsules/bottle	 	12 bottles/case
	Pertzye [***]	 	NDC 59767-[***]-XX	 	100 capsules/bottle	 	12 bottles/case
	Pertzye [***]	 	NDC 59767-[***]-XX	 	250 capsules/bottle	 	6 bottles/case
				
	Samples	 		 		 	
	Pertzye [***]	 	NDC 59767-[***]-XX	 	100 capsules/bottle	 	12 bottles/case
	Pertzye [***]	 	NDC 59767-[***]-XX	 	20 capsules/bottle	 	12bottles/case
	Pertzye [***]	 	NDC 59767-XXX XX	 	20 capsules/bottle	 	12bottles/case
	Pertzye [***]	 	NDC 59767-[***]-XX	 	100 capsules/bottle	 	12bottles/case
	Pertzye [***]	 	NDC 59767-[***]-XX	 	20 capsules/bottle	 	12bottles/case

  
 [***]
Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

 Corrected and Restated 
  

 EXHIBIT B 
 CAPITALIZED TERMS 
  

			
	 Defined Term
	  	 Section

		
	 Agreement
	  	Preamble
	 AMA
	  	16
	 AMA Guidelines
	  	16
	 Audit Termination
	  	12(c)(viii)
	 Average Manufacturer Price
	  	10(b)
	 Back Up Manufacturing Data
	  	5(b)(iv)
	 Best Price
	  	10(b)
	 CF
	  	Recitals
	 CF Market
	  	7(b)
	 CF Percentage
	  	7(b)
	 CF Sales Force
	  	3(a)
	 cGMP
	  	5(a)
	 Claim
	  	21(a)(i)
	 Committed Promotional Spend
	  	3(e)
	 Confidentiality Agreement
	  	18(a)
	 Complaints
	  	Exhibit F
	 Copromotion Revenue
	  	Recitals
	 Cooperating Party
	  	18(c)
	 CRTX
	  	Preamble
	 CRTX Orders
	  	6(a)
	 CRTX Quarterly Report
	  	4(e)
	 DCI
	  	Recitals
	 DCI Audit Refusal Notice
	  	12(c)(vii)
	 DCI Audit Refusal Termination
	  	12(c)(vii)
	 DCI Quarterly Report
	  	5(j)
	 DCI’s Returned Goods Policy
	  	Exhibit N
	 Early Termination
	  	12(c)(vi)
	 Effective Date
	  	Preamble
	 EPI
	  	Recitals
	 Escrow Agreement
	  	Exhibit G
	 Escrow Payment
	  	8(a)(ii)
	 Estimated Revenue Split
	  	6(b)
	 Extension Term
	  	11(b)
	 Facilities
	  	13(c)
	 FDA
	  	3(c)
	 Fifth Milestone
	  	8(f)
	 First Milestone
	  	8(b)
	 Force Majeure Event
	  	19
	 Fourth Milestone
	  	8(e)
	 FTE
	  	3(a)

 Corrected and Restated 
  

			
	 GMP Audit Report
	  	13(l)(i)
	 Governmental Programs
	  	9(a)
	 GPOs
	  	1(a)
	 Indemnified Party
	  	21(a)(i)
	 Indemnifying Party
	  	21(a)(i)
	 Indemnified Persons
	  	21(a)(i)
	 Initial Press Release
	  	18(b)
	 Initial Term
	  	11(a)
	 Insolvency Opinion
	  	12(c)(v)
	 Loan and Security Agreement
	  	13(c)
	 Losses
	  	21(a)(i)
	 NDC
	  	10(a)
	 Net Sales
	  	7(a)
	 Nonrefundable Payment
	  	8(a)(i)
	 PADERS
	  	5(d)
	 Partnership
	  	29
	 Party
	  	Recitals
	 Parties
	  	Recitals
	 PDMA
	  	3(g)
	 Products
	  	Exhibit A
	 Promotion Year
	  	3(e)
	 Quality Agreement
	  	5(a)
	 Requesting Party
	  	18(c)
	 Revenue Split
	  	Recitals
	 Second Milestone
	  	8(c)
	 SPL
	  	13(l)(i)
	 Steering Committee
	  	2(a)
	 Target Customers
	  	1(a)
	 Territory
	  	1(d)
	 Third Milestone
	  	8(d)
	 Trademarks
	  	1(h)
	 Transaction Documents
	  	29

 Corrected and Restated 
  

 EXHIBIT C 
 MATTERS WITHIN THE PURVIEW OF THE STEERING COMMITTEE 
  

	 	•	 	 Review and approval of previous meeting minutes 

  

	 	•	 	 First line dispute resolution 

  

	 	•	 	 Review of packaging, promotional labeling and other promotional materials, including use of trademarks 

 

	 	•	 	 Review of discounting practices in connection with reconciliation of the effect of Government Rebates on Net Sales calculations

  

	 	•	 	 Oversight of sales force training and PRB review of sales materials 

 

	 	•	 	 Setting and changing of Estimated Revenue Split 

  

	 	•	 	 Reviewing Quarterly Reports 

  

	 	•	 	 Planning for and allocating product samples 

 Corrected and Restated 
  

 EXHIBIT D 
 DCI MEDICAL INFORMATION REQUEST AND MEDICAL REPORTING FORMS 
 FORM
F-GEN-027-01 
 Rev. #1 
 Effective Date:                      

DIGESTIVE CARE, INC. 
 Complaint Report Form 
  

									
	QA ONLY	  	Complaint #	  	ADE (Y/N):	  	By:	  	Date:

  

	
	 1.      COMPLAINT RECEIPT
AND SUMMARY

	 Prepared By
 (Name and Title):

	When (date) and how (oral, phone, fax,
email, mail, other) was the complaint received, and who reported it (name and contact information)?
	 
	 
	 
	Provide a description of the nature of
the complaint, including when (date) and where did this event happen and/or was it observed, how long did it last or is it on-going, what (if any) material/ product (name, strength and lot number) was involved
	 
	 

  

	
	 2.      COMPLAINT
PROCESSING (by QA)

	 Describe any additional information collected to confirm the complaint.
 (attach copies of
supporting documentation)

	 
	 
	 
	 Is an investigation required:

 ̈  Yes (attach a copy of the Investigation Report and supporting
documentation)
  

 ̈  No; Reason:

	 Complaint Processed By:
 (name and title)

  

			
	
3.      COMPLAINT CLOSURE (by the Head of the Quality Unit or designee)

	
1.      If the complaint represents a post marketing adverse drug experience (ADE),
determine if the event meets the requirements (serious/unexpected) for reporting to the FDA.
  ̈  No;         ̈  Yes; AE#

	 If yes, date submitted to
FDA:
 (attach a copy of the report)

	 Was a reply sent to the complainant:

 ̈  Yes; Date:
                                 (attach a copy)

 
  ̈  No;
Reason:

	 Date Complaint Closed:

 
	  	
By:
  

 Corrected and Restated 
  

 EXHIBIT E 
 MATTERS TO BE INCLUDED IN THE QUARTERLY REPORT 
 By CRTX 

 

	 	•	 	 Analysis of full prescribing data on which Net Sales in the CF Market determination is based 

 

	 	•	 	 FTE Expansion and hiring plans 

  

	 	•	 	 Rolling 12 month forecast of prescription and sample demand for Products 

 

	 	•	 	 Such other items as the Steering Committee may reasonably request 

 By DCI: 
  

	 	•	 	 Analysis of full prescribing data on which Net Sales in the CF Market determination is based 

 

	 	•	 	 Finished Product inventory levels and a summary of the production schedule during the quarter 

 

	 	•	 	 Status of any open manufacturing, supply chain or regulatory issues, including periodic progress reports on compliance with post-marketing commitments.

  

	 	•	 	 Such other items as the Steering Committee may reasonably request 

 Corrected and Restated 
  

 Exhibit F 
 Quality Agreement 
 Commercial Product 

Between 

CORNERSTONE THERAPEUTICS, INC. 
 a corporation existing under the laws of Delaware 
 (“CRTX”)

 -and- 
 DIGESTIVE CARE, INC. 
 a corporate existing under the laws of Pennsylvania

 (“DCI”) 
 Specific sites covered by this Quality Agreement: 
 Digestive Care, Inc.

 1120 Win Drive 
 Bethlehem, PA 18017 
 Effective Date: APRIL xx, 2013 

Version No. 00 

SIGNATURES OF APPROVAL: 
  

					
	DCI:	 		 	
		 		 	  

	Tibor Sipos, PhD	 		 	Signature
	President and Chief Scientific Officer	 		 	
		 		 	  

		 		 	Date
			
	CRTX:	 		 	
		 		 	  

	Alan T. Roberts	 		 	Signature
	VP, Scientific Affairs	 		 	
		 		 	  

		 		 	Date

 Corrected and Restated 
  

	I.	INTRODUCTION and SCOPE 

 This Quality Agreement defines the duties and responsibilities of Digestive Care, Inc. (DCI) and Cornerstone Therapeutics, Inc. (CRTX) for the supply of PERTZYE® (pancrelipase) Delayed-Release Capsules (the “Product”) under the terms of a marketing and sales licensing
agreement (the “Agreement”). 
 Under the Agreement, DCI is required to ensure that the Product is manufactured in accordance with
Current Good Manufacturing Practices (“cGMP”), is correctly labeled, and conforms to the Specifications as contained in the FDA Approved NDA #22-175 at the time of release and throughout the established shelf-life. The purpose of the
Quality Agreement is to ensure that only conforming Product is distributed and sold. 
 The parties desire to allocate responsibility for
matters relating to the Product. A detailed checklist of the activities associated with this agreement is contained in Appendix A. The responsibility for each activity is assigned to DCI and/or CRTX indicated as marked with “X” in the
appropriate box of the checklist. If marked with “(X)”, cooperation is required from the designated party. 
  

	II.	GENERAL PROVISIONS and DEFINITIONS 

  

	1	Any communications about the subject matter of this Quality Agreement will be directed, in the first instance, to the person(s) identified in Appendix B as responsible
for Quality. 

  

	2	Capitalized terms not otherwise defined herein will have the same meaning specified in the Agreement. 

 

	3	If any provision of this Quality Agreement should be, or found, invalid or unenforceable by law, the rest of the provisions will remain valid and binding and the
parties will negotiate a valid provision which meets as close as possible the objective of the invalid provision. 

  

	4	If this Quality Agreement requires modification so that the party affected cannot be reasonably expected to continue to perform under this Quality Agreement, then the
parties will negotiate and revise the Quality Agreement accordingly. 

  

	5	Any amendment of this Quality Agreement will be made in writing and signed by both parties. 

 

	6	The Effective Date is set forth on the cover page of this Quality Agreement and will remain valid until the Quality obligations under the applicable Agreements have
been fulfilled. 

  

	7	If there is any conflict between the terms of this Quality Agreement and the Agreement, the Agreement will control except for any specific Quality issue.

 For purposes of this Quality Agreement, the following definitions shall apply: 

 

	 	•	 	 “FDA” means the United States Food and Drug Administration. 

 Corrected and Restated 
  

	 	•	 	 “Regulatory Authority” means the FDA or other entity involved in the authorizations as required to operate a pharmaceutical manufacturing
Facility. 

  

	 	•	 	 “Facility” means the DCI facility located in Bethlehem, PA. 

 

	 	•	 	 “GMP” means the current Good Manufacturing Practices for Finished Pharmaceuticals promulgated by the FDA, Title 21 Code of Federal
Regulations (CFR), Sections 210 and 211, as amended. 

  

	 	•	 	 “Applicable Laws” means the rules and regulations governing the operations of a pharmaceutical manufacturing Facility, as promulgated by the
FDA or other Regulatory Authority. 

  

	 	•	 	 “Specifications” means the testing procedures and quality control data, requirements, or standards for control of the identity, strength,
quality, and purity of the Product. 

  

	 	•	 	 “SOPs” means the standard operating procedures in effect at DCI or CRTX. 

 

	 	•	 	 “Complaint” means any communication received via any type of oral and/or written format, regarding the possible failure of a drug product to
meet any of its specifications. This also includes any communication that may represent a post marketing adverse drug experience as defined herein. 

  

	 	•	 	 Adverse Drug Experience (ADE): Per 21CFR§314.80 “Any adverse event associated with the use of a drug in humans, whether or not
considered drug related, including the following: An adverse event occurring in the course of the use of a drug product in professional practice; an adverse event occurring from drug overdose whether accidental or intentional; an adverse event
occurring from drug abuse; an adverse event occurring from drug withdrawal; and any failure of expected pharmacological action.” 

  

	 	•	 	 Serious adverse drug experience: Per 21CFR§314.80 “Any adverse drug experience occurring at any dose that results in any of the
following outcomes: Death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.” Any
important medical events that may require medical or surgical intervention to prevent one of the outcomes in this definition is also considered a serious adverse drug experience. 

 

	 	•	 	 Unexpected adverse drug experience: Per 21CFR§314.80 “Any adverse drug experience that is not listed in the current labeling for the
drug product.” 

 Corrected and Restated 
  

 APPENDIX A: RESPONSIBILITY CHECKLIST 

 

					
	 RESPONSIBILITIES
	 	CRTX	 	DCI
			
	Regulatory Authorizations & GMP Compliance	 		 	
			
	1. Responsible for obtaining and maintaining the permits, licenses, registrations and other authorizations as required, to operate a pharmaceutical manufacturing
Facility.	 		 	X
			
	2. Responsible for obtaining and maintaining regulatory approvals for the Product, including without limitation, marketing and post-marketing approvals.	 		 	X
			
	3. Responsible for maintaining and operating the Facility in compliance with cGMP regulations, and applicable environmental, occupational health and safety laws.	 		 	X
			
	4. Will not employ or use the services of any individual who is debarred by FDA or who has engaged in activities that could lead to being debarred.	 	X	 	X
			
	5. Upon reasonable notice, will permit CRTX to conduct audits of records applicable to the manufacture and control of the Product. CRTX audits are limited to one (1) audit per
calendar year unless for cause.	 		 	X
			
	6. Will provide CRTX the finished product Certificate of Analysis for each batch released.	 		 	X
			
	7. CRTX will provide regulatory and medical review on CRTX promotional items. During the CRTX review process, promotional items will be provided to DCI for review, approval and
submission to FDA. CRTX will not disseminate any promotional items without approval from DCI.	 	X	 	X
			
	Regulatory Authority Actions	 		 	
			
	8. Responsible for handling regulatory inquiries related to the Product.	 		 	X
			
	9. Promptly notify the other party of any Regulatory Authority communications, requests or investigations relating to the Product.	 	X	 	X
			
	10. Promptly notify CRTX of any Regulatory Authority notice of inspection or inspection of the Facilities directly relating to the Product.	 		 	X
			
	11. Provide copies of any Form FDA-483’s, Warning Letters or the like from Regulatory Authorities relating to items 7 and 8.	 	X	 	X

 Corrected and Restated 
  

 APPENDIX A: RESPONSIBILITY CHECKLIST 

 

					
	 RESPONSIBILITIES
	 	CRTX	 	DCI
			
	Customer Service, Complaints & AEs	 		 	
			
	12. Maintain a call center for collecting information, managing and responding to customer inquiries relating to the Products by the respective customer base.	 	X	 	X
			
	13. CRTX field sales force shall submit inquiries deemed to meet the definition of a Complaint to the CRTX call center using the CRTX SOP. Complaints received by the CRTX call
center will be submitted to DCI in a format containing the information required on the DCI designated form. Such information will be made available to DCI as soon as possible but in no case later than 72 hours of receipt by CRTX, or at such earlier
time as may be appropriate under applicable regulations.	 	X	 	
			
	14. Responsible for the timely investigation of Complaints originating from CRTX customers.	 	(X)	 	X
			
	15. Responsible for reporting adverse event information (Expedited and Periodic Adverse Drug Experience Reports) to appropriate Regulatory Authorities in accordance with applicable
legal requirements.	 		 	X
			
	16. Responsible for adverse event related activities including but not limited to reviewing scientific literature, signal detection, record retention, maintaining data privacy,
ad-hoc reports requested by Regulatory Authorities and audits.	 		 	X
			
	17. As needed, CRTX will retrieve complaint sample(s) and forward them to DCI in a timely manner to aid a complete and comprehensive investigation.	 	X	 	
			
	18. Responsible for regulatory reporting obligations, including the timely reporting of Complaints to appropriate regulatory authorities in accordance with applicable legal
requirements.	 		 	X
			
	Product Failures, NDA Field Alerts & Recalls	 		 	
			
	19. DCI will notify CRTX within three (3) business days, of any information that indicates a Product supplied to CRTX has failed to remain within specifications.	 		 	X
			
	20. Responsible for making decisions and managing actions relating to NDA Field Alerts, or Recalls of the Product. CRTX will assist in these activities as requested by
DCI.	 	(X)	 	X

 Corrected and Restated 
  

 APPENDIX B: CONTACT LIST 

 

					
	  	 	 DCI
	 	 CRTX

		
	Responsibility	 	Quality
	Name	 	Tibor Sipos, PhD	 	Jennifer Fetterolf
	Title	 	President and Chief Scientific Officer	 	Senior Manager, Quality Assurance
	Phone	 	610-882-5950	 	919-678-6641
	Fax	 	610-882-0349	 	919-678-6599
	E-mail	 	tsipos@digestivecare.com	 	jennifer.fetterolf@crtx.com
	Address	 	 1120 Win Drive
 Bethlehem, PA 18017
	 	 1255 Crescent Green Drive
 Suite 250 Cary, NC 27518

		
	Responsibility	 	Regulatory Affairs
	Name	 	Eve Damiano, MS, RAC	 	Ashlie Adams, MS, RAC
	Title	 	Sr. VP, Operations	 	Sr. Manager, Regulatory Affairs
	Phone	 	610-882-5950	 	919-678-6602
	Fax	 	610-882-0349	 	919-678-6599
	E-mail	 	edamiano@digestivecare.com	 	Ashlie.adams@crtx.com
	Address	 	 1120 Win Drive
 Bethlehem, PA 18017
	 	 1255 Crescent Green Drive
 Suite 250
 Cary, NC 27518

		
	Responsibility	 	Scientific/Medical Information
	Name	 	Tibor Sipos, PhD	 	Jo Anne Thomas
	Title	 	President and Chief Scientific Officer	 	Medical Information Manager
	Phone	 	610-882-5950	 	919-678-6529
	Fax	 	610-882-0349	 	919-678-6599
	E-mail	 	tsipos@digestivecare.com	 	Joanne.thomas@crtx.com
	Address	 	 1120 Win Drive
 Bethlehem, PA 18017
	 	 1255 Crescent Green Drive
 Suite 250 Cary, NC 27518

		
	Responsibility	 	Account Manager
	Name	 	Steve Berens	 	Jason Beyer
	Title	 	VP, Sales and Marketing	 	Senior Product Manager
	Phone	 	610-882-5950	 	919-678-6622
	Fax	 	610-882-0349	 	919-678-6599
	E-mail	 	sberens@digestivecare.com	 	jason.beyer@crtx.com
	Address	 	 1120 Win Drive
 Bethlehem, PA 18017
	 	 1255 Crescent Green Drive
 Suite 250 Cary, NC 27518

 Corrected and Restated 
  

 EXHIBIT G 
 Back Up Manufacturing Data Escrow Agreement 
 This Back Up Manufacturing Data
Escrow Agreement (the “Agreement”), by and between Digestive Care, Inc., a Pennsylvania corporation, having a place of business at 1120 Win Drive, Bethlehem, PA 18017 (“DCI”) and Cornerstone Therapeutics Inc., a Delaware
corporation (“CRTX”), having a place of business at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518, is Exhibit G to the License and Distribution Agreement executed contemporaneously herewith by DCI and CRTX, and is incorporated
therein. This Agreement is separately and independently enforceable. This Agreement shall be deemed effective as to DCI and CRTX on the Effective Date of the aforementioned License and Distribution Agreement. This Agreement shall be deemed effective
as to the Escrow Agent on the date signed by the Escrow Agent. 
 WHEREAS, in order to induce CRTX to enter into the aforementioned
License and Distribution Agreement, DCI has agreed to escrow Back Up Manufacturing Data, 
 WHEREAS, DCI and CRTX intend this Agreement
to be considered as supplementary to the aforementioned License and Distribution Agreement, pursuant to Title 11 United States [Bankruptcy] Code, Section 365(n), and 
 WHEREAS. Escrow Agent desires to administer the Escrow pursuant to the terms of this Agreement, 
 NOW THEREFORE, in consideration of the mutual covenants set forth in this Agreement, and intending to be legally bound hereby, DCI, CRTX and Escrow
Agent agree as follows: 
  

	1.	Term of Agreement. The Term of this Agreement shall be of even term with the aforementioned License and Distribution Agreement executed by DCI and CRTX and any
extensions thereto. 

  

	2.	DCI Responsibilities. 

  

	 	(a)	Escrow Agent Candidates Selection. DCI’s Steering Committee representatives shall cooperate with CRTX’s Steering Committee representatives to promptly
identify and select an independent and unaffiliated candidate to serve as Escrow Agent, or in the case of the resignation of Escrow Agent, to promptly identify and select an independent and unaffiliated candidate to serve as successor Escrow Agent.

  

	 	(b)	 Data Deposit. DCI shall submit deposit material as provided by Paragraph 5(b)(iv) of the aforementioned License and Distribution Agreement
(“Deposit 

 Corrected and Restated 
  

	 	
Material”) to Escrow Agent within thirty (30) days of Escrow Agent’s signing this Agreement. DCI shall also update Deposit Material from time to time to assure Deposit Material
constitutes the latest update or edition of such material. At the time of each deposit or update, DCI shall provide to both CRTX and Escrow Agent with an accurate and complete description of initial or updated Deposit Material. DCI agrees, subject
to the receipt of customary confidentiality undertakings, to provide a mutually acceptable third party with such access to the Deposit Material as may be reasonably necessary to verify, on behalf of CRTX, its accuracy and completeness

  

	 	(c)	Deposit Expenses. DCI shall alone be responsible for paying the costs and expenses of making and submitting the Deposit Materials and descriptions thereof.

  

	 	(d)	Steering Committee Co-chair Identification. DCI shall keep Escrow Agent apprised of the identity of their co-chair of the Steering Committee under the License
and Distribution Agreement as the person whose written instructions to Escrow Agent will be legally binding on DCI. DCI’s Steering Committee co-chair will maintain the accuracy of their name and contact information provided to the Escrow Agent
during the Term of this Agreement and advise Escrow Agent of successor Steering Committee co-chair. 

  

	3.	CRTX Responsibilities. 

  

	 	(a)	Escrow Agent Candidates Selection. CRTX’s Steering Committee representatives shall cooperate with DCI’s Steering Committee representatives to promptly
identify and select an independent and unaffiliated candidate to serve as Escrow Agent, or in the case of the resignation of Escrow Agent, to promptly identify and select an independent and unaffiliated candidate to serve as successor Escrow Agent.

  

	 	(b)	Escrow Agent Fees and Expenses. CRTX shall alone be responsible for paying the costs and expenses of the Escrow Agent. 

 

	 	(c)	Steering Committee Co-chair Identification. CRTX shall keep Escrow Agent apprised of the identity of their co-chair of the Steering Committee under the License
and Distribution Agreement as the person whose written instructions to Escrow Agent will be legally binding on CRTX. CRTX’s Steering Committee co-chair will maintain the accuracy of their name and contact information provided to the Escrow
Agent during the Term of this Agreement and advise Escrow Agent of successor Steering Committee co-chair. 

 Corrected and Restated 
  

	4.	Escrow Agent Responsibilities. 

  

	 	(a)	Safeguard Deposit Material. Escrow Agent shall hold Deposit Material in a Bank Safe Deposit Box or similar vault, and restrict access to the Deposit Material
except as specified in this Escrow Agreement. 

  

	 	(b)	Issue authentications. Escrow Agent shall provide DCI’s and CRTX’s Steering Committee co-chairs with a unique confidential authorizing code with which
to authenticate written instructions to Escrow Agent. 

  

	 	(b)	Conditions for Release, Disbursement or Destruction of Deposit Materials. 

 

	 	(i)	Mutual Consent. Upon receipt of written instructions executed and authenticated by the Steering Committee co-chairs of both DCI and CRTX, the Escrow Agent shall
release, replace, return, or destroy Deposit Materials in accordance with the written instructions. 

  

	 	(ii)	Unilateral Request. In the event that Escrow Agent receives a written request executed and authenticated by either DCI’s or CRTX’s Steering Committee
co-chair to release, replace, return, or destroy Deposit Materials, Escrow Agent shall send notice and a copy of such request to the non-requesting party delivered by a commercial next day courier that provides confirmation of receipt, or by U.S.
Postal Service Certified Mail, return receipt requested. The non-requesting party shall then have ten (10) business days from receipt of said notice to deliver to the Escrow Agent a written representation that a release condition of the License
and Distribution Agreement has not occurred or has been cured (“Contrary Instructions”). Upon receipt of Contrary Instructions, Escrow Agent shall promptly send a copy to the requesting party, and notify both parties that there is a
dispute to be resolved pursuant to the Disputes provisions of this Agreement. Escrow Agent will continue to safeguard the Deposit Material without release pending dispute resolution pursuant to the Disputes provisions of this Agreement; withdrawal
of the Contrary Instructions, or receipt of an order from a court of competent jurisdiction. 

  

	 	(c)	Resignation of Escrow Agent. In the event that Escrow Agent contemplates resignation prior to the expiration of the Term of this Agreement and any extensions
thereto, it shall so notify both DCI and CRTX in writing, and those parties will have 30 days in which to designate a successor Escrow Agent and request transfer of the Deposit Material to the successor Escrow Agent. 

 

	5.	 Disputes. Disputes shall be escalated pursuant to the terms of the License and Distribution Agreement and settled by arbitration in accordance
with the then current Center for Public Resources Rules for Non-Administered Arbitration of Business Disputes by three (3) independent and impartial arbitrators. Each Party, DCI, CRTX and Escrow Agent shall appoint an arbitrator. The
arbitration shall be governed by the United States Arbitration Act, 9 U.S.C. §1-16. The Parties agree that limited discovery shall be allowed in accordance with the Federal Rules of Civil Procedure,

 Corrected and Restated 
  

	 	
Rule 26(a)(1) - (3) (as in effect on the date hereof), which disclosure shall be made within sixty (60) days of the initiation of arbitration. All issues regarding compliance with this
mandatory disclosure shall be decided by the arbitrators pursuant to the Federal Rules of Civil Procedure, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof. DCI and CRTX shall jointly
and severally be responsible for payment of Escrow Agent’s costs and expenses incurred in connection with the arbitration. The arbitrators shall determine the dispute in accordance with the substantive rules of law (but not the rules of
procedure) of the State of New York. The place of arbitration shall be in the State of New York. In the event that the parties do not cooperate to arbitrate the dispute, the Escrow Agent can submit the matter to a court of competent jurisdiction as
an interpleader or similar action. 

  

	6.	Severability. The intention of the Parties is to comply fully with all laws and public policies, and this Agreement shall be construed consistently with all laws
and public policies to the extent possible. If and to the extent that any arbitration panel determines that it is impossible to construe any provision of this Agreement consistently with any law or public policy and consequently holds that provision
to be invalid, such holding shall in no way affect the validity of the other provisions of this Agreement, which shall remain in full force and effect. 

  

	7.	Failure or Omission. No failure or omission by a Party to insist upon or enforce any of the terms of this Agreement shall be deemed a waiver of such terms.

  

	8.	Successors and Assigns. 

  

	 	(a)	Successors. This Agreement is binding on the Parties and their successors in interest. 

 

	 	(b)	Assignment by DCI or CRTX. In the event that either DCI or CRTX contemplates the assignment of any of its rights or obligations under this Agreement, it shall so
notify the other Party in writing, and the other Party will have thirty (30) days in which either to consent in writing to such assignment or to provide written notice of its intention to terminate this Agreement effective ninety (90) days
from the date of such notice, provided, however, that no consent shall be required to an assignment to a party that is the majority owner of, is majority owned by, or under common majority ownership with, the assigning party, or is the acquirer or
successor to all of the business of the assigning party to which this Agreement relates. 

  

	 	(c)	Assignment by Escrow Agent. In the event that Escrow Agent contemplates the assignment of any of its rights or obligations under this Agreement, it shall so
notify both DCI and CRTX in writing, and those parties will have thirty (30) days in which either to consent in writing to such assignment or request transfer of the Deposit Material to a successor Escrow Agent. 

 Corrected and Restated 
  

	9.	Complete Agreement. This Agreement, along with any written amendments signed by the parties constitutes the entire agreement between the Parties, and cancels and
supersedes any and all previous agreements between the Parties with respect to the subject matter hereof. All modifications or amendments hereto must be in writing and signed by all Parties. No renewal, termination or cancellation of this Agreement,
or modification or waiver of any of the provisions herein contained, or any future representation, promise or condition in connection with the subject matter hereof, shall be binding unless it is made in writing, dated subsequently and signed on its
behalf by an authorized officer of each Party. 

  

	10.	Headings. The headings of the several sections hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the
several sections hereof. The Parties acknowledge they have thoroughly reviewed this Agreement and mutually agreed upon its terms. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives: 

 

									
	Digestive Care, Inc.:	 		 	Cornerstone Therapeutics, Inc.:
					
	By:	 	  
	 		 	By:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

 ESCROW AGENT: 
  

			
	Organization Name	 	  

		
	 By:
	 	  

		
	 Title:
	 	  

		
	 Date:
	 	  

 Corrected and Restated 
  

 EXHIBIT H 
 ESTIMATED REVENUE SPLIT 
 Illustration: Calculation of Transfer Price (as defined per
agreement) 
  

							
	Note: All figures shown for illustration purposes only.	  		  			
	Units Ordered	  		  	 	[***]	  
	WAC Price	  		  	 	[***]	  
	Product Returns Allowance %	  		  	 	[***]	  
	Chargebacks/Price Adjustments Allowance %	  		  	 	[***]	  
	Rebates Allowance %	  		  	 	[***]	  
	Cash Discounts Allowance %	  		  	 	[***]	  
			
	 CRTX Invoice to Target Customer
	  		  			
	Invoice Value	  	(1)	  	 	[***]	  
	Agreed upon Transfer Price %	  	(2)	  	 	[***]	  
	 Transfer Price Payment
	  	[***]	  	 	[***]	  

  

	(1)	Units X WAC Price 

	(2)	Calculated as [***] share of net sales using estimated allowances of [***]%. % Allowance will be adjusted quarterly using actual data from previous quarter.

  
 [***]
Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

 Corrected and Restated 
  

 EXHIBIT I 
 EXAMPLE OF 
  

	 	•	 	 CALCULATION OF NET SALES IN THE CF MARKET; 

 Illustration: Calculation of Net Sales (as defined per agreement) 
  

							
	 Note: All figures shown for illustration purposes only.
	  		 			
	 Ex-factory Units Sold
	  		 	 	[***]	  
	 Units Pulled Through Target Customers
	  		 	 	[***]	  
	 WAC Price
	  		 	 	[***]	  
	 Product Returns Allowance %
	  		 	 	[***]	  
	 Chargebacks/Price Adjustments Allowance %
	  		 	 	[***]	  
	 Rebates Allowance %
	  		 	 	[***]	  
	 Cash Discounts Allowance %
	  		 	 	[***]	  
			
	 Method I: Recognize revenue upon shipment method (if supportable under GAAP):
	  		 			
			
	 Gross Revenue
	  	(1)	 	$	[***]	  
	 Less: Product Returns Allowance
	  	(2)	 	 	[***]	  
	 Less: Chargebacks/Price Adjustments Allowance
	  	(2)	 	 	[***]	  
	 Less: Rebates Allowance
	  	(2)	 	 	[***]	  
	 Less: Cash Discounts Allowance
	  	(2)	 	 	[***]	  
	 Less: Other Allowances, if applicable and allowable
	  	(2)	 	 	—  	  
		  		 	  
	  
	 
	 Net Sales
	  		 	$	[***]	  
		  		 	  
	  
	 
			
	 Method II: Recognition revenue upon pull-through method (default method):
	  		 			
			
	 Gross Revenue
	  	(1)	 	$	[***]	  
	 Less: Product Returns Allowance
	  	(2)	 	 	[***]	  
	 Less: Chargebacks/Price Adjustments Allowance
	  	(2)	 	 	[***]	  
	 Less: Rebates Allowance
	  	(2)	 	 	[***]	  
	 Less: Cash Discounts Allowance
	  	(2)	 	 	[***]	  
	 Less: Other Allowances, if applicable and allowable
	  	(2)	 	 	—  	  
		  		 	  
	  
	 
	 Net Sales
	  		 	$	[***]	  
		  		 	  
	  
	 

  

	(1)	Units X WAC Price 

	(2)	% Allowance calculated using historical experience from similar sales (i.e. same customers, distribution channel, etc.) 

	(3)	Co-pay assistance programs are not allowable under definition of Net Sales per the agreement. 

 
 [***] Confidential portions of the
exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

 Corrected and Restated 
  

 EXHIBIT J 
 EXAMPLE OF RECONCILIATION OF SALES RELATED TO CF PATIENTS 
 Illustration - Calculation
of Pertzye Sales related to CF patients 
 Rx Claims by Product and Disease Group 

Key Assumption: Claims data for this calculation needs to be based on patients who filled their Rx through Traditional (non-SP) Channel 

 

																									
	 Table 2: Rx Claims by Product and
Disease Group
	 
	 Drug
	  	CF Diagnosis Code	 	 	All Diagnosis Codes	 
	  	Claims	 	 	Quantity
(Pills)	 	 	Average
Quantity	 	 	Claims	 	 	Quantity
(Pills)	 	 	Average
Quantity	 
	 Pertzye
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Total Unique PEP Market
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 

  

							
	 Pertzye Quantity (Pills) for CF
	  	 	[***	] 	 	
	 Total Pertzye Quantity (Pills)
	  	 	[***	] 	 	
	 % Pertzye Quantity for CF
	  	 	[***	] 	 	The ratio will be calculated each quarter based on data
		  				 	availability

 Key Assumption: All (100%) sales reported in the SP Channel will include diagnosis and will not need to have a
ratio applied. If any sales through SP channel do not include a diagnosis, the Rx ratio will be applied. 
  

[***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

 Corrected and Restated 
  

 INITIAL PRESS RELEASE 

 
 

 
 Press Release 
 Cornerstone Therapeutics Acquires Exclusive U.S. Marketing Rights to
PERTZYE® (pancrelipase) for Treatment of Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

 Acquisition of Marketing Rights to FDA Approved Therapy Expands Company’s Cystic Fibrosis Portfolio

 CARY, N.C., MayX, 2013 - Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company
focused on commercializing products for the hospital and adjacent specialty markets, today announced it has entered into an agreement with Digestive Care, Inc. (DCI) to acquire exclusive U.S. rights to market PERTZYE® (pancrelipase) for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF). PERTZYE is
a unique pancreatic enzyme product and is protected by several U.S. patents1. The PERTZYE formulation was previously marketed by DCI for more than a decade under the trade name PANCRECARB® MS-16. It is estimated that about 90% of patients with CF receive pancreatic enzyme replacement therapy (PERT2) with the therapeutic category experiencing 24% annual
growth from 2008-2012. 
 “The acquisition of the exclusive U.S. marketing rights formarket-ready PERTZYE will have an
immediate revenue impact for Cornerstone,” said Craig A. Collard, Cornerstone’s Chief Executive Officer. “With net sales of PERT products reaching approximately $200 million in the CF category in 2012, we see significant opportunity
for growth. Also, the addition of PERTZYE complements Cornerstone’s launch of the CF drug BETHKIS®
(tobramycin inhalation solution) later this year. This is yet another strategic step in our commitment to building a portfolio of industry-leading brands for the growing U.S. hospital and adjacent specialty markets.” 

Dr. Tibor Sipos, President and Chief Scientific Officer of DCI, stated “We are pleased to partner with Cornerstone and are confident that their
CF-focused marketing efforts will enhance patient accessibility to PERTZYE and provide support for educational programs. Going forward, DCI’s sales and marketing efforts for PERTZYE will be focused on meeting the needs of patients with EPI due
to conditions other than CF in the U.S. market.” 

 Corrected and Restated 
  

 ABOUT PERTZYE (pancrelipase) DELAYED-RELEASE CAPSULES 

PERTZYE is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Exocrine Pancreatic Insufficiency due to cystic fibrosis or other
conditions. PERTZYE is the only FDA approved PERT containing bicarbonate-buffered, enteric-coated microspheres. This uniqueformulation was designed to optimize the pH environment for enzyme activity and nutrient absorption1. PERTZYE is currently
available in two strengths: 8,000 and 16,000 USP units of lipase/capsule. 
 IMPORTANT SAFETY INFORMATION ABOUT PERTZYE 

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYEexceed 2,500 lipase
units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day). 
 To avoid irritation of oral mucosa, do not
chew PERTZYE or retain in the mouth. 
 Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or
renal impairment. 
 Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

 There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE. 

The most common adverse reactions (3 10% of patients treated with PERTZYE) are diarrhea, dyspepsia, and
cough. 
 PERTZYE full Prescribing Information and Medication Guide are available at www.pertzye.com. 

IMPORTANT SAFETY INFORMATION ABOUT BETHKIS 
 BETHKIS® is indicated for the management of cystic fibrosis
patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia. 

BETHKIS is contraindicated in patients with a known hypersensitivity to any aminoglycoside. 
 Bronchospasm can occur with inhalation of BETHKIS. Bronchospasm and wheezing should be treated as medically appropriate. Caution should be exercised when prescribing BETHKIS to patients with known or
suspected auditory, vestibular, renal, or neuromuscular dysfunction. Audiograms, serum 

 Corrected and Restated 
  

 
concentration, and renal function should be monitored as appropriate. Avoid concurrent and/or sequential use of BETHKIS with other drugs with neurotoxic or ototoxic potential.BETHKIS should not
be administered concurrently with ethacrynic acid, furosemide, urea, or mannitol. Aminoglycosides may aggravate muscle weakness because of a potential curare-like effect on neuromuscular function. Fetal harm can occur when aminoglycosides are
administered to a pregnant woman. Apprise women of the potential hazard to the fetus. Common adverse reactions (more than 5%) occurring more frequently in BETHKIS patients are forced expiratory volume decreased, rales, red blood cell sedimentation
rate increased, and dysphonia. 
 TRADEMARKS 
 PERTZYE® (pancrelipase) is owned by Digestive Care, Inc. and is
licensed to Cornerstone Therapeutics for sales and marketing purposes in the United States. BETHKIS® (Tobramycin
Inhalation Solution) is owned by Chiesi Farmaceutici S.p.A. and is licensed to Cornerstone Therapeutics for sales and marketing purposes in the United States. 
 About Cornerstone Therapeutics Inc. 
 Cornerstone Therapeutics Inc. (NASDAQ: CRTX),
headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company’s strategy are to focus its commercial and development efforts
in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within
the Company’s focus areas; and generate revenues by marketing approved generic products through the Company’s wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. For more information, visit www.crtx.com. 

About Digestive Care, Inc. 
 Digestive
Care, Inc., headquartered in Bethlehem, PA, is a fully integrated pharmaceutical company, founded in 1990, dedicated to developing unique pharmaceutical products to alleviate complications and symptoms of gastrointestinal disorders. For more
information, visit www.digestivecare.com. 
 Safe Harbor Statement 
 This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements
of historical fact, including our strategy and our future operations and opportunities, including our plans regarding the manner and timing for the launch and sale of PERTZYE, constitute forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements as a result of various important factors, including our ability to satisfy FDA and other regulatory requirements, our ability to develop and maintain the necessary sales, marketing,
supply chain and distribution capabilities to successfully commercialize PERTZYE, and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K 

 Corrected and Restated 
  

 
filed with the Securities and Exchange Commission (the SEC) on March 14, 2013 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our
expectations and beliefs only as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at
some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as may be required by law. Our forward-looking statements do not reflect the potential impact of
any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. These forward-looking statements should not be relied upon as representing our views as of any date after the
date of this release. 
 Contacts 
 CRTX Investor Relations Contact: 
 Josh Franklin, Vice President, Strategy and Business
Development, +1-919-678-6520, 
 josh.franklin@crtx.com 
 CRTX Media Relations Contact: 
 Fleishman-Hillard, Andrea Moody, +1-919-457-0743, 

andrea.moody@fleishman.com 
 DCI Contact:

 Steve Berens, Vice President Sales and Marketing, +1-610-882-5950; 
 sberens@disestivecare.com 
  

	1.	U.S. Patent Numbers: 5,260,074; 5,302,400; 5,324,514; 5,460,812; 5,578,304; 5,750,104. 

 

	2.	“Patient Registry Annual Report 2011.” Cystic Fibrosis Foundation. Cystic Fibrosis Foundation. Date Accessed
5/3/13<http://www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf>. 

PERTZYE®
 (pancrelipase) Delayed-Release Capsules are manufactured in the USA by Digestive Care, Inc., Bethlehem, PA. 
 G-Q213-01

 Corrected and Restated 
  

 EXHIBIT L 
 CONFIDENTIALITY AGREEMENT 
 This CONFIDENTIAL DISCLOSURE AGREEMENT
(“Agreement”), effective as of December 3, 2012 (“Effective Date”), is made by and between CORNERSTONE THERAPEUTICS INC., a Delaware corporation, with its principal address located at 1255
Crescent Green Drive, Suite 250, Cary, NC 27518 (“CRTX”) and Digestive Care, Inc., a Pennsylvania corporation with its principal address located at 1120 Win Drive, Bethlehem, PA 18017 (“COMPANY”). 

In consideration of authorized agents and/or employees of CRTX and COMPANY disclosing and/or providing certain information to the other
party, the premises and the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 

1. Purpose. CRTX and COMPANY wish to explore a future potential relationship (“Potential Relationship”) relating
to potential business collaboration and it may be desirable during such exploration for CRTX and/or COMPANY to disclose or provide Confidential Information to the other Party. 
 2. Definition. “Confidential Information” shall mean all confidential, proprietary or nonpublic information (including financial information), ideas, concepts, data, data
compilations, research, reports, protocols, techniques, methods, processes, plans, strategies, know-how, materials and documents in any form or medium (including oral, written, tangible, intangible or electronic) concerning the science, business,
business opportunities, activities and/or operations of CRTX and COMPANY, including without limitation, current and future (i) products, research and development activities, including clinical trials and results; (ii) intellectual property
(including without limitation patent applications, inventions, processes, compounds, discoveries, formulae, technology, computer software, databases, and documentation); (iii) investors, manufacturers, suppliers, vendors, competitors, and
customers; and (iv) legal and regulatory activities, communications, approvals. 
 3. Exceptions. Confidential
Information does not include information which (i) is in the possession of the recipient party at the time of disclosure hereunder as evidenced by adequate written records; (ii) prior to or after the time of disclosure becomes public
knowledge, not as a result of any inaction or action of the recipient party; (iii) was received by the recipient party from a third party having a right to disclose it, or (iv) is developed by or for the recipient party independently of
disclosures hereunder, as evidenced by adequate written records 
 4. Legally Required Disclosure.
If either party (for this purpose, the “Obligated Party”) or any of its employees, directors, officers or agents (“Representatives”) is requested or required (by oral questions, interrogatories, requests for
information or documents in legal proceedings, subpoena, civil investigative demand or other similar process, or by the rules or regulations of any regulatory authority having jurisdiction over the Obligated Party or if NASDAQ or a stock exchange on
which the Obligated Party’s securities are -traded)
to disclose any of the Confidential Information of the other party, the Obligated Party shall, except as prohibited by law, provide the other party with prompt written notice of any such request or requirement so that the other party may seek, at
the other party’s expense, a protective order or other remedy and/or waive compliance with the provisions of this Agreement. If the other party seeks a protective order or other remedy, the Obligated Party shall provide such cooperation as the
other party shall reasonably request. It in the absence of a protective order or other remedy or the receipt by the Obligated Party of a waiver from the other party, the Obligated Party or any of its Representatives is required to disclose the
Confidential Information to any person, the Obligated 

 Corrected and Restated 
  

 
Party or its Representatives may, without liability hereunder, disclose to such person only that portion of the Confidential Information which is legally required to be disclosed, provided that
the Obligated Party and its Representatives shall exercise reasonable efforts to minimize the disclosure of the Confidential Information. 
 5. Non-Use and Nondisclosure. CRTX and COMPANY each agree not to use any Confidential Information disclosed hereunder to it for its own or others’ benefit or for any purpose not directly
related to the Potential Relationship. CRTX and COMPANY, shall not disclose, provide, communicate, reveal, share, provide access to, transfer, copy, distribute or publish any Confidential Information received hereunder at any time to any parson or
entity, other than to its employees who need to know it for exploration of the Potential Relationship, and who were previously informed of the terms of this Agreement end their obligations thereunder. CRTX and COMPANY shall notify the
other party in writing of any known misuse or misappropriation of any Confidential Information, and shall cooperate with any efforts by the other party to secure its return and protect its rights therein. 

6. Return of Materials. Upon the request of CRTX and/or COMPANY, any and all originals and copies of materials or documents (in
any form or media) which contain Confidential Information and were provided to the other party shall be promptly returned or destroyed, except that the recipient party may retain one copy of the Confidential Information in the possession of its
legal counsel solely for the purpose of monitoring its obligations under this Agreement and copies included on the recipient’s computer system or backup system are not required to be removed if reasonably burdensome to do so. 

7. No License. Nothing in this Agreement is intended to grant to CRTX or COMPANY any right or license under any intellectual
property rights of the other party (including any intellectual property rights in the Confidential Information), except the limited right to use and disclose Confidential Information as expressly set forth herein. 

8. Term. The term of this Agreement shall be four (4) years from the Effective Date. 

9. Remedies. In view of the difficulties of placing a monetary value on the Confidential Information, and the irreparable harm
CRTX and COMPANY would suffer from the unauthorized use or disclosure of its Confidential Information, the parties agree that, in the event of any unauthorized disclosure by CRTX or COMPANY or unauthorized use of the Confidential Information of the
other party, the other party shall be entitled to seek a preliminary and final injunction without the necessity of posting any bond or undertaking, and shall be entitled to recover all costs and expenses, including attorneys’ fees, incurred in
any legal action arising under this Agreement. This remedy is separate and apart from any other remedy that CRTX or COMPANY might have. 
 10. Representations and Warranties. CRTX and COMPANY each represents and warrants to the other party that it has the right to enter into this Agreement and that it is not and will not be party to
any other agreement, expressed or implied, that would limit its performance hereunder. CRTX and COMPANY make no warranty of any kind, expressed or implied, with respect to the Confidential Information, and hereby disclaim any and al] such
warranties, including without limitation warranties of merchantability, non-infringement, value, reliability, accuracy, suitability and fitness for a particular use. CRTX and COMPANY acknowledge that the disclosure of the Confidential Information
hereunder is made on an “as is” basis. 
 11. Assignment. CRTX and COMPANY shall not assign this
Agreement, in whole or in part, without the other party’s prior written consent which is not to be unreasonably withheld. Any purported assignment in violation of this paragraph 11 shall be null and void ab initio and of no force or
effect. In the event of a permitted assignment, this Agreement shall inure to the benefit of and bind the parties and their respective assigns. 

 Corrected and Restated 
  

 12. Miscellaneous. This Agreement contains the entire understanding between the
parties, superseding all prior or contemporaneous communications, agreements and understandings whether oral or written concerning the subject matter hereof. This Agreement, including this paragraph 12, may not be modified except by a written
agreement signed by both parties. The failure of CRTX or COMPANY to require strict performance by the other party of any provision in this Agreement will not waive or diminish CRTX’s or COMPANY’s right to demand strict performance
thereafter of that or any other provision hereof. If any provision of this Agreement shall be held by a court of competent jurisdiction to be illegal, invalid or unenforceable, the remaining provisions shall continue in full force and effect. The
parties acknowledge that they are independent contractors and that no agency, partnership, joint venture or other relationship is created by this Agreement. All facsimile or electronic copies of this Agreement will be deemed to be duplicate
originals. 
 13. Trading in Securities. COMPANY acknowledges and agrees that (i) CRTX is a publicly-held
company and (ii) COMPANY is aware and has advised its employees, directors, officers and agents involved in the exploration of the Potential Relationship that applicable securities laws prohibit any person who is aware of material, non-public
information about a company obtained directly or indirectly from that company from purchasing or selling securities of such company or from communicating such information to any other person under circumstances in which it is reasonably foreseeable
that such person is likely to purchase or sell such securities. 
 14. No Further Agreement CRTX and COMPANY both
expressly acknowledge that the execution of this Agreement and the disclosure of Confidential Information hereunder do not obligate either party to enter into any further agreement or understanding, whether relating to the Confidential Information,
the Potential Relationship or otherwise. 
 15. Governing Law. This Agreement shall be governed by the laws of the State
of Delaware, U.S.A. Each party hereto submits to the exclusive jurisdiction of the state and federal courts in Delaware, U.S.A. for any suit, action or proceeding relating to this Agreement. 

[Remainder of page left intentionally blank.] 

 Corrected and Restated 
  

 SIGNATURE PAGE TO CONFIDENTIAL DISCLOSURE AGREEMENT 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date. 

 

					
	CRTX:
	
	CORNERSTONE THERAPEUTICS INC.
		
	By:	 	 /s/ Josh
Franklin            12/5/12

	Name:	 	Josh Franklin
	Title:	 	VP, Strategy and Business Development
	
	COMPANY:
	
	DIGESTIVE CARE, INC.
		
	By:	 	 /s/ Tibor
Sipos            12/3/12

	Name:	 	Tibor Sipos, Ph.D.
	Title:	 	President & CEO

 Corrected and Restated 
  

 EXHIBIT L-1 

AMENDMENTS to the CONFIDENTIAL DISCLOSURE AGREEMENT 
 These AMENDMENTS (the Amendments) to the CONFIDENTIAL DISCLOSURE AGREEMENT (the “Agreement”), by and between Digestive Care, Inc., a Pennsylvania corporation, having a place of business at 1120
Win Drive, Bethlehem, PA 18017-7059, U.S.A. (“DCI” or “COMPANY”) and Cornerstone Therapeutics Inc., a Delaware corporation (“CRTX”), having a place of business at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518, is
Exhibit L-1 to the License and Distribution Agreement executed contemporaneously herewith by DCI and CRTX, and is incorporated therein. This Agreement is separately and independently enforceable. This Agreement shall be deemed effective on the
Effective Date of the aforementioned License and Distribution Agreement. 
 WHEREAS, CRTX and DCI entered into the Agreement effective
December 3, 2012, and the Agreement provides in paragraph 12, “This Agreement, including this paragraph 12, may not be modified except by a written agreement signed by both parties.” and 

WHEREAS, DCI and CRTX deem it desirable and in their mutual best interests to amend the Agreement only to the extent provided by these Amendments,
and otherwise keep it unchanged and legally binding on the parties and in all other aspects in full force and effect. 

NOW THEREFORE, in consideration of the mutual covenants set forth in this Agreement,
and intending to be legally bound hereby, DCI, CRTX and amend the Agreement as follows: 
  

	6.	1. Purpose. is deleted and replaced with: 

 1. Purpose. CRTX and DCI have negotiated and entered into a License and Distribution Agreement and in the process of negotiating that agreement and during the term of that agreement it has become
necessary for CRTX and DCI to disclose and provide Confidential Information and Highly Confidential Information to the other party. 
  

	7.	2. Definition. is amended as follows: 

 The heading Definition. is deleted and replaced with Definitions. 
 The
following paragraph is added: 
 “Highly Confidential Information” shall mean Confidential Information designated by a
party and marked, “HIGHLY CONFIDENTIAL — ACCESS AND DISSEMINATION RESTRICTED TO PARTIES LEGAL COUNSEL, AUDITORS AND THE FOLLOWING NAMED INDIVIDUALS” followed by the names of the individuals. 

 Corrected and Restated 
  

	8.	5. Non-Use and Nondisclosure. is amended by adding the following paragraph: 

Highly Confidential Information shall be delivered to a designated person, via personal delivery or by a commercial next day courier that
provides restricted delivery and confirmation of receipt, or by U.S. Postal Service Certified Mail, restricted delivery, return receipt requested as a single hard copy. Highly Confidential Information may be used by designated named individuals in
executing their responsibilities but may not otherwise be used or disseminated within their organization. Highly Confidential Information shall not be scanned, photographed, photocopied, or copied to disk, CD ROM, thumb drive or any other form of
machine readable or mobile media unless access to such electronic version of the information is password protected and thereby limited to the persons identified in the definition of that term. Highly Confidential Information shall be kept in a
locked filing cabinet within a locked and otherwise secure room in the office of the recipient party’s legal counsel. 
  

	9.	6. Return of Materials. is amended by adding the following sentence: 

 Highly Confidential Information shall be returned or destroyed, or retained by the recipient party in the possession of its legal counsel solely for the purpose of monitoring its obligations under this
Agreement. 
  

	10.	8. Term. is deleted and replaced with “8. Term. The Term of this Agreement shall be of even term with the License and Distribution Agreement executed
by DCI and CRTX, and any extensions thereto, plus four (4) years.” 

 IN WITNESS WHEREOF, the Parties have caused these
Amendments to be executed by their duly authorized representatives: 
  

									
	Digestive Care, Inc.:	 		 	Cornerstone Therapeutics, Inc.:
					
	By:	 	  
	 		 	By:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

 Corrected and Restated 
  

 EXHIBIT M 
 ESCROW RELEASE AND USE OF PROCEEDS 
 The funds deposited in escrow as the Escrow Payment
under Section 8(a), shall be released only in the following circumstances: 
 Within thirty (30) days after the completion of the GMP
Audit and CRTX’s receipt of the GMP Audit Report: 
  

	 	•	 	 If CRTX notifies DCI that it wishes to exercise either (i) its right of Early Termination pursuant to Section 12(c)(vi), or (ii) its
right of DCI Audit Refusal Termination pursuant to Section 12(c)(vii), the escrow agent shall pay all of the escrow funds to CRTX; 

  

	 	•	 	 If CRTX notifies DCI that it does not wish to exercise its right of Early Termination or its right of DCI Audit Refusal Termination, the escrow agent
shall pay $2,000,000 to DCI 

 Within thirty (30) days after receipt by CRTX of SPL’s plan to address the corrective
actions and/or deficiencies, if any, referenced in the GMP Audit Report 
  

	 	•	 	 If CRTX notifies DCI that it wishes to exercise its right of Audit Termination pursuant to Section 12(c)(viii), the escrow agent shall pay all of
the funds then remaining in the escrow to CRTX; 

  

	 	•	 	 If CRTX notifies DCI that it does not wish to exercise its right of Audit Termination, or if CRTX has not exercised such right within thirty
(30) days after CRTX acknowledgement of receipt by CRTX of SPL’s plan to address the corrective actions and/or deficiencies, if any, referenced in the GMP Audit Report, the escrow agent shall pay all of the funds then remaining in the
escrow to DCI. 

 Funds so released to DCI shall be used in the manner described, and in satisfaction of the particular
obligations identified, below: 
 1. No more than $2 million, in payment for the outstanding balance, if any, on DCI’s revolving line of
credit with TD Bank, by two party check; 
 2. No more than $2 million, in payment for the outstanding balance, if any, due to Scientific
Proteins Laboratories LLC, or SPL, in payment for the DMF Access Fee obligations to be paid upon receipt of the consent referenced in Section 13(l)(iii), or otherwise in accordance with payment terms stated in the supply agreement between DCI
and SPL, by two-party check; and 

 Corrected and Restated 
  

 3. The remainder to fund completion of the post-marketing commitments referenced in Section 13(e),
the corrective actions (if any) referenced in the GMP Audit Report delivered pursuant to Section 13(l) and any other business expense occurring in the ordinary course of DCI’s business, but not to fund any cash transfer or distribution to
any other company or person, including affiliated companies or shareholders of DCI, that is not in the ordinary course of business. 

 Corrected and Restated 
  

 EXHIBIT N 
 RETURNED GOODS POLICY 
  
 

 
 Effective July 3, 2012 
 RETURN GOODS POLICY 
 All returns must be pre-approved by Digestive Care,
Inc. No credit will be given for unauthorized returns. Every return must have a Return Authorization number which can be obtained by faxing to 610-882-0349, emailing to customerservice@digestivecare.com, or submitting through the
web-portal. In order to insure that credit is properly issued, the Return Authorization number must be printed on the outside of the carton, as well as on any corresponding documentation. Returned product must not be damaged by fire, flood or
negligence, and the safety seals on the bottles must be intact. Expired propduct must be returned within 12 months after expiration date. Products are to be sent to Digestive Care, Inc. at 1120 Win Drive, Bethlehem, PA 18017. All
transportation costs are to be paid by the customer (product returned “collect” will be refused). Returns are subject to credit or exchange at the discretion of Digestive Care, Inc. Credits issued will be at the price paid by the customer
after any discounts and allowances. Credit will not be given for product sold on a non-returnable basis. Credit will only be issued for returns of bottles where the seal is unbroken. Credit will be issued for returned product as mandated by
state or federal law. Credit will not be given for products obtained in violation of local, state or federal regulations.  
 1120 Win Drive, Bethlehem, PA 18017-7059    Phone (610) 882-5950    Fax (610) 882-0349 

www.disestivecare.com 

 Corrected and Restated 
  

 EXHIBIT O 
 EXAMPLE OF REVENUE SPLIT PAYMENT CALCULATION, AS OFFSET BY ESTIMATED REVENUE SPLIT AMOUNTS PAID BY CRTX 
 Illustration: Calculation of Royalty Payable by CRTX (as defined per agreement) 
  

																			
	Note: All figures shown for illustration purposes only.	  	 	 	 	 	 	 	 	 	Based on Diagnosis Code	 	 	 	 
	 	  	 	 	Total	 	 	CF-related	 	 	Non-CF Related	 	 	No	 
	 	  	 	 	Code	 	 	 	 	 	 	 	 	 	 
	 CRTX Net Sales (from Net Sales Calculation, Exhibit I)
	  		 	 	[***	] 	 				 				 			
	 Net Sales classified based on Target Customer data
	  	(1)	 				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 CF-Percentage applied to unidentified net sales (from Exhibit J)
	  	[***]	 				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 CRTX Net Sales in CF Market and non-CF Market
	  		 				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  		 				 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
						
	 Royalty %
	  		 				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  		 				 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Royalty Payable to PARK
	  	[***]	 				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  		 				 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Less: Transfer Price Payments
	  		 	 	[***	] 	 				 				 			
	 Net Royalty Payable To (Receivable From) PARK
	  	A	 	 	[***	] 	 				 				 			

  

	(1)	Derived directly from quarterly data provided by Target Customer. Unidentifiable data will be designated as CF or Non-CF percentage per Exhibit J.

 Illustration: Calculation of Copromotion Revenue Payable by PARK (as defined per agreement) 

 

																			
	Note: All figures shown for illustration purposes only.	  	 	  	 	 	 	 	 	 	Based on Diagnosis Code	 	 	 	 
	 	  	 	  	Total	 	 	CF-related	 	 	Non-CF Related	 	 	No	 
	 	  	 	  	Code	 	 	 	 	 	 	 	 	 	 
	 PARK Net Sales
	  		  	 	[***	] 	 				 				 			
	 Net Sales classified based on IMS data
	  	(2)	  				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 CF-Percentage applied to unidentified net sales (from Exhibit J)
	  	[***]	  				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 PARK Net Sales in CF Market and non-CF Market
	  		  				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 Copromotion Revenue %
	  		  				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 Copromotion Revenue Payable to CRTX
	  		  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 Less: Actual Government Rebates Paid related to CF Net Sales
	  	(3)	  	 	[***	] 	 				 				 			
	 Net Copromotion Revenue Payable To (Receivable From) CRTX
	  	B	  	 	[***	] 	 				 				 			
						
	 Net Payable To (Receivable From) PARK
	  	=A-B	  	 	[***	] 	 				 				 			

  

	(2)	Derived directly from quarterly data provided by IMS and other PARK customer data (if applicable). Unidentifiable data will be designated as CF or Non-CF using CF-
percentage per Exhibit J. 

	(3)	Calculated based on actual rebates paid by PARK * CF Percentage (per Exhibit J) as shown below: 

 

					
	 Total Rebates Paid
	  	 	[***	] 
	 CF Percentage (Exhibit J)
	  	 	[***	] 
		  	  
	  
	 
	 Rebates Paid related to CF-Market
	  	 	[***	] 

  
 [***]
Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

 Corrected and Restated 
  

 EXHIBIT P 
 PROFESSIONAL SAMPLE PRICING 
 CRTX shall order samples according to the procedure and with
the lead times and payment terms as the Parties may agree. 
 CRTX shall pay DCI directly for samples as follows: [***] of WAC 

 
 [***] Confidential portions of the
exhibit have been omitted and filed separately with the Securities and Exchange Commission. 

 Corrected and Restated 
  

 EXHIBIT Q 
 Escrow Payment Escrow Agreement 
 This Funds Escrow Agreement
(“Agreement”), by and between Digestive Care, Inc., a Pennsylvania corporation, having a place of business at 1120 Win Drive, Bethlehem, PA 18017 (“DCI”) and Cornerstone Therapeutics Inc., a Delaware corporation
(“CRTX”), having a place of business at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518, and Dominic Farole, Esq., 1005 Chestnut Street, Suite 101, Coplay, PA 18037 (“Escrow Agent”) is Exhibit Q to the License and
Distribution Agreement executed contemporaneously herewith by DCI and CRTX, and is incorporated therein. This Agreement is separately and independently enforceable. This Agreement shall be deemed effective as to DCI and CRTX on the Effective Date of
the aforementioned License and Distribution Agreement. This Agreement shall be deemed effective as to the Escrow Agent on the date signed by the Escrow Agent. 
 WHEREAS, in pursuant to the aforementioned License and Distribution Agreement, DCI and CRTX have agreed to escrow the initial payment by CRTX to DCI, 

WHEREAS, DCI and CRTX intend this Agreement to be considered as supplementary to the aforementioned License and Distribution Agreement, pursuant
to Title 11 United States [Bankruptcy] Code, Section 365(n), and 
 WHEREAS. Escrow Agent desires to administer the Escrow pursuant
to the terms of this Agreement, 
 NOW THEREFORE, in consideration of the
mutual covenants set forth in this Agreement, and intending to be legally bound hereby, DCI, CRTX, and Escrow Agent agree as follows: 
  

	1.	Establishment of Fund. CRTX has caused or will cause to be deposited with Susquehanna Bank, (“Custodian”) the sum of ten million dollars
($10,000.000.00), (such sum, or the balance thereof remaining from time to time being referred to herein as the “Fund”). 

  

	2.	Treatment of Fund. The monies constituting the Fund shall be deposited in a segregated, interest-bearing account pursuant to the terms of this Escrow Agreement.
Such account shall be styled Pertzye Initial License Payment Fund, with federal tax identification no.             . The fund shall be held by Custodian under their “CDAR”
agreement with Escrow Agent whereby the full amount of the Fund shall be FDIC insured. 

  

	3.	Escrow Procedures and Payment Instruction. The Fund, together with all interest earned thereon, which interest shall become and remain a part of the Fund, shall
be held and disbursed in accordance with the Conditions for Disbursement as set forth below. The parties each acknowledge that Escrow Agent is authorized to use the wire transfer information in this section to disburse funds.

 Corrected and Restated 
  

	4.	Conditions for Disbursement of the Fund. 

The Fund shall be disbursed in the following manner: 
  

	 	(a)	Mutual Consent. Upon receipt of written instructions executed and authenticated from the Steering Committee co-chairs of both DCI and CRTX, the Escrow Agent
shall disburse Fund monies in accordance with the written instructions, which shall stipulate the basis for such instructions with reference to Exhibit M of the License and Distribution Agreement. 

 

	 	(b)	Unilateral Request. In the event that Escrow Agent receives a written instructions executed and authenticated by either DCI’s or CRTX’s Steering
Committee co-chair to disburse monies from the Fund, and such instructions stipulate the basis for such instructions with reference to Exhibit M of the License and Distribution Agreement, Escrow Agent shall send notice and a copy of such request
with the confidential authenticating code removed. The non-requesting party shall then have ten (10) business days from receipt of said notice to give the Escrow Agent notice that a disbursement condition of the License and Distribution
Agreement has not occurred (“Contrary Instructions”). Upon receipt of Contrary Instructions, Escrow Agent shall promptly send a copy, with confidential authenticating code removed, to the requesting party, and notify both parties that
there is a dispute to be resolved pursuant to the Disputes provisions of this Agreement. Escrow Agent will not disburse Funds pending dispute resolution pursuant to the Disputes provisions of this Agreement; withdrawal of the Contrary Instructions,
or receipt of an order from a court of competent jurisdiction. 

  

	 	(c)	Wire Transfer Information. 

 If to DCI: 
  

			
	Bank Name:	 	  

	Bank Address:	 	  

		 	  

	ABA Number:	 	  

	Account Name:	 	  

		 	  

	Account Number:	 	  

 Corrected and Restated 
  

 If to CRTX: 

 

			
	Bank Name:	 	  

	Bank Address:	 	  

		 	  

	ABA Number:	 	  

	Account Name:	 	  

		 	  

	Account Number:	 	  

  

	5.	Term. This Agreement shall terminate upon the disbursement of the balance of the Fund in accordance with the provisions of Section 3 hereof.

  

	6.	Escrow Agent Compensation. For and in consideration of Trust Agent’s agreement to disburse the Trust Account in accordance with the terms and conditions
contained in this Agreement, the Escrow Agent shall receive a flat fee of One Thousand Dollars ($1,000.00), which shall be paid to Escrow Agent from the first deposit paid to the Fund. 

 

	7.	Escrow Agent Responsibilities. 

 (a) Fund Account Setup. Escrow Agent shall obtain a Tax ID from the IRS in the name of the Fund, open a Fund Account under a CDERS Deposit Placement Agreement with Custodian. 

(b) Issue Instruction authentications. Escrow Agent shall separately provide DCI’s and CRTX’s Steering Committee
co-chairs with a unique confidential authorizing code with which to authenticate written instructions to Escrow Agent. 
 (c)
Order Disbursements. Escrow Agent shall only authorize distribution from the Fund in accordance with this Agreement. 
  

	8.	Limitation of Escrow Agent’s Liability. Escrow Agent hereby acknowledges he is acting in a fiduciary capacity for the benefit of both DCI and CRTX , and
Escrow Agent shall perform his obligations under this Agreement in accordance with all laws applicable to similarly situated fiduciaries, but Escrow Agent shall not be responsible or liable in any manner whatsoever for: 

 

	 	(a)	the sufficiency, correctness, or timing of the deposit of monies into the Fund. 

 

	 	(b)	uninsured amounts over the FDIC insurance limits held by Custodian. 

 Corrected and Restated 
  

	 	(c)	Escrow Agent’s reliance on a properly authenticated written instructions from designated representatives of either or both of the other parties to this agreement.

  

	 	(d)	the compliance or noncompliance of any other person with any other agreement notwithstanding that such other agreement may be referred to herein or that the Escrow
Agent may have knowledge thereof. 

  

	 	(e)	services other than his role as a fiduciary pursuant to the terms of this Agreement, unless there is a separate written agreement signed by Escrow Agent for such
services. 

  

	9.	Indemnification of Escrow Agent. DCI and CRTX do hereby jointly and severally agree to indemnify Escrow Agent for any and all costs and expenses, including
attorneys fees, that the Escrow Agent may sustain arising out of acts of the Escrow Agent in execution of, and reasonably required in furtherance of the Escrow Agent’s responsibilities set forth in this Agreement. 

 

	10.	Successor Escrow Agent. In the event that Escrow Agent is unable to unwilling to continue prior to the expiration of the Term of this Agreement and any
extensions thereto, DCI shall identify one or more prospective successor escrow agents, subject to CRTX’s approval in writing, which shall not be unreasonably withheld, and both parties will notify the Custodian of the authority of the
Successor Escrow Agent. 

  

	11.	Disputes. Disputes shall be settled by arbitration in accordance with the then current Center for Public Resources Rules for Non-Administered Arbitration of
Business Disputes by three (3) independent and impartial arbitrators. DCI and CRTX shall appoint an arbitrator, and the two arbitrators will select a third. The arbitration shall be governed by the United States Arbitration Act, 9 U.S.C.
§1-16. The Parties agree that limited discovery shall be allowed in accordance with the Federal Rules of Civil Procedure, Rule 26(a)(1) - (3) (as in effect on the date hereof), which disclosure shall be made within sixty (60) days of
the initiation of arbitration. All issues regarding compliance with this mandatory disclosure shall be decided by the arbitrators pursuant to the Federal Rules of Civil Procedure, and judgment upon the award rendered by the arbitrators may be
entered by any court having jurisdiction thereof. DCI and CRTX shall jointly and severally be responsible for payment of Escrow Agent’s costs and expenses incurred in connection with the arbitration. The arbitrators shall determine the dispute
in accordance with the substantive rules of law (but not the rules of procedure) of the State of New York. The place of arbitration shall be in the State of New York. In the event that the parties do not cooperate to arbitrate the dispute, the
Escrow Agent can submit the matter to a court of competent jurisdiction as an interpleader or similar action. 

  

	12.	 Notices. Wherever notice is required or permitted hereunder, it shall be by personal delivery, overnight delivery service, or sent by facsimile
transmission, with electronic confirmation, properly directed to the Party at its address and contact information 

 Corrected and Restated 
  

	 	
listed below, and shall be effective upon receipt in the case of personal delivery, overnight delivery or facsimile. Said address and contact information may be changed from time to time by
similar written notice. 

  

					
	If to CRTX:	  		 	If to DCI:
			
	Cornerstone Therapeutics Inc.	  		 	Digestive Care Inc.
	1255 Crescent Green Drive	  		 	1120 Win Drive
	Cary, NC 27518	  		 	Bethlehem, PA 18017
			
	Attention: General Counsel	  		 	Attention: Chief Executive Officer
	Phone: 919 678 6611	  		 	Phone: 610-882-5950
	Fax: 919 678 6599	  		 	Fax: 610-882-0349
			
	If to Escrow Agent:	  		 	
			
	Law Office of	  		 	
	Dominic A. Farole, P.C	  		 	
			
	1005 Chestnut Street, Suite 101	  		 	
	Coplay, PA 18037	  		 	
	Phone: (610) 502-2720	  		 	
	Fax: (610) 502-2710	  		 	

  

	13.	Severability. The intention of the Parties is to comply fully with all laws and public policies, and this Agreement shall be construed consistently with all laws
and public policies to the extent possible. If and to the extent that any arbitration panel determines that it is impossible to construe any provision of this Agreement consistently with any law or public policy and consequently holds that provision
to be invalid, such holding shall in no way affect the validity of the other provisions of this Agreement, which shall remain in full force and effect. 

  

	14.	Failures or Omissions. No failure or omission by a Party to insist upon or enforce any of the terms of this Agreement shall be deemed a waiver of such terms.

  

	15.	Successors and Assigns. 

  

	 	(d)	Successors. This Agreement is binding on the Parties and their successors in interest. 

 

	 	(e)	 Assignment by DCI or CRTX. In the event that either DCI or CRTX contemplates the assignment of any of its rights or obligations under this
Agreement, it shall so notify the other Party in writing, and the other Party will have 30 days in which either to consent in writing to such assignment or to provide written notice of its intention to terminate this Agreement effective 90 days from
the date of such notice, provided, however, that no consent shall be 

 Corrected and Restated 
  

	 	
required to an assignment to a party that is the majority owner of, is majority owned by, or under common majority ownership with, the assigning party, or is the acquirer or successor to all of
the business of the assigning party to which this Agreement relates. 

  

	 	(f)	Assignment by Escrow Agent. In the event that Escrow Agent contemplates the assignment of any of its rights or obligations under this Agreement, it shall so
notify both DCI and CRTX in writing, and those parties will have 30 days in which either to consent in writing to such assignment or to appoint a successor Escrow Agent. 

 

	16.	Complete Agreement. This Agreement, along with any written amendments signed by the parties constitutes the entire agreement between the Parties, and cancels and
supersedes any and all previous agreements between the Parties with respect to the subject matter hereof. All modifications or amendments hereto must be in writing and signed by all Parties. No renewal, termination or cancellation of this Agreement,
or modification or waiver of any of the provisions herein contained, or any future representation, promise or condition in connection with the subject matter hereof, shall be binding unless it is made in writing, dated subsequently and signed on its
behalf by an authorized officer of each Party. 

  

	17.	Headings. The headings of the several sections hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the
several sections hereof. The Parties acknowledge they have thoroughly reviewed this Agreement and mutually agreed upon its terms. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives: 

 

									
	Digestive Care, Inc.:	 		 	Cornerstone Therapeutics, Inc.:
					
	By:	 	  
	 		 	By:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

				
	Dominic Farole, Esq., Escrow Agent	 		 		 	
					
	By:	 	  
	 		 		 	
					
	Date:	 	  
	 		 		 	

 Corrected and Restated 
  

 EXHIBIT R 
 Partnership Assets 
 The real property located at 1120 Win Drive, Bethlehem, PA 18017

 Corrected and Restated 
  

 EXHIBIT S 
 Partnership Letter of Assurance 
 The undersigned, being all the partners of The Sipos
Family Partnership (the “Partnership”), are providing this letter of assurance pursuant to the License and Distribution Agreement by and between Digestive Care, Inc., a Pennsylvania corporation, having a place of business at 1120 Win
Drive, Bethlehem, PA 18017 (“DCI”) and Cornerstone Therapeutics Inc., a Delaware corporation (“CRTX”), having a place of business at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518, and the other agreements executed in
connection with that Agreement (the “Transaction Documents”). 
 The Partnership hereby acknowledges and assures CRTX that 

 

	 	•	 	 it is a Pennsylvania Limited Partnership duly registered and qualified, and in good standing, under the laws of the State of Pennsylvania;

  

	 	•	 	 it has read and understood the terms of the Transaction Documents; 

 

	 	•	 	 it will take such actions, give such assurances and do such things as may be necessary to implement the Transaction Documents and otherwise ensure that
the purposes and intent of the Parties as expressed in this Agreement are not frustrated and 

  

	 	•	 	 it will not take any action or fail to take any action that would conflict with DCI’s obligations under any of the Transaction Documents, violate
CRTX’s rights under any of the Transaction Documents, frustrate the purposes and intent of the Parties as expressed in the Transaction Documents or result in CRTX not receiving any of the benefits of the Transaction Documents

  

	 	•	 	 CRTX may rely on the signatures of any one of the undersigned General Partners for the purposes of binding the partnership in connection with any of
the foregoing matters. 

 Executed this      day of May, 2013 

 

	
	  

	Tibor Sipos, General Partner
	
	  

	Tibor Sipos, Jr., General Partner

 Corrected and Restated 
  

	
	  

	Elizabeth J. Sipos
	
	  

	Miklos Sipos
	
	  

	Gabor Sipos

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]